



HAL
open science

Non-Exosomal and Exosome-Derived miRNAs as Promising Biomarkers in Canine Mammary Cancer.

P. Petroušková, N. Hudáková, M. Maloveská, F. Humeník, Dasa Cizkova

► To cite this version:

P. Petroušková, N. Hudáková, M. Maloveská, F. Humeník, Dasa Cizkova. Non-Exosomal and Exosome-Derived miRNAs as Promising Biomarkers in Canine Mammary Cancer.. *Life*, 2022, *Life* (Basel, Switzerland), 12, 10.3390/life12040524 . hal-04428717

HAL Id: hal-04428717

<https://hal.univ-lille.fr/hal-04428717>

Submitted on 31 Jan 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License

Review

Non-Exosomal and Exosome-Derived miRNAs as Promising Biomarkers in Canine Mammary Cancer

Patricia Petroušková ¹ , Nikola Hudáková ¹, Marcela Maloveská ¹, Filip Humeník ¹ and Dasa Cizkova ^{1,2,*}

¹ Centre of Experimental and Clinical Regenerative Medicine, The University of Veterinary Medicine and Pharmacy, Komenského 73, 041 81 Košice, Slovakia; patricia.petrouskova@uvlf.sk (P.P.); nikola.hudakova@student.uvlf.sk (N.H.); marcela.maloveska@uvlf.sk (M.M.); filip.humenik@uvlf.sk (F.H.)
² Institute of Neuroimmunology, Slovak Academy of Sciences, Dúbravská Cesta 9, 845 10 Bratislava, Slovakia
* Correspondence: dasa.cizkova@uvlf.sk; Tel.: +421-918-752-157

Abstract: Canine mammary cancer (CMC), similar to human breast cancer (HBC) in many aspects, is the most common neoplasm associated with significant mortality in female dogs. Due to the limited therapy options, biomarkers are highly desirable for early clinical diagnosis or cancer progression monitoring. Since the discovery of microRNAs (miRNAs or miRs) as post-transcriptional gene regulators, they have become attractive biomarkers in oncological research. Except for intracellular miRNAs and cell-free miRNAs, exosome-derived miRNAs (exomiRs) have drawn much attention in recent years as biomarkers for cancer detection. Analysis of exosomes represents a non-invasive, pain-free, time- and money-saving alternative to conventional tissue biopsy. The purpose of this review is to provide a summary of miRNAs that come from non-exosomal sources (canine mammary tumor, mammary tumor cell lines or canine blood serum) and from exosomes as promising biomarkers of CMC based on the current literature. As is discussed, some of the miRNAs postulated as diagnostic or prognostic biomarkers in CMC were also altered in HBC (such as miR-21, miR-29b, miR-141, miR-429, miR-200c, miR-497, miR-210, miR-96, miR-18a, miR19b, miR-20b, miR-93, miR-101, miR-105a, miR-130a, miR-200c, miR-340, miR-486), which may be considered as potential disease-specific biomarkers in both CMC and HBC.

Keywords: canine; mammary cancer; biomarker; miRNA; exosome



Citation: Petroušková, P.; Hudáková, N.; Maloveská, M.; Humeník, F.; Cizkova, D. Non-Exosomal and Exosome-Derived miRNAs as Promising Biomarkers in Canine Mammary Cancer. *Life* **2022**, *12*, 524. <https://doi.org/10.3390/life12040524>

Academic Editors: Lara Console and Mariafrancesca Scalise

Received: 24 February 2022

Accepted: 30 March 2022

Published: 1 April 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Canine Mammary Cancer

1.1. General Information and Risk Factors

In veterinary medicine, canine cancer represents a severe clinical problem [1]. Approximately one in four dogs suffers cancer at some stage in their life and almost half of dogs over the age of 10 die due to neoplasia [2]. Tumors of the mammary glands are the second most commonly diagnosed type of cancer in dogs, with certain breeds, such as Labrador Retrievers, Cocker Spaniels, Irish Setters, German Shepherds, mixed-breed dogs, and miniature and Toy Poodles, and are over-represented in terms of high risk of neoplasia and mortality [3]. Mammary tumors typically develop in intact female dogs or elderly spayed (ovariohysterectomised) bitches, usually between 8 and 10 years old [4,5]. This problem is especially significant in Europe, where bitches are usually spayed at an older age [4]. However, the precise prevalence of canine mammary tumors differs from study to study due to the dog breeds and age and geographic location [6]. Biaioni et al. reported that canine mammary tumors were the most frequent tumor in Italy, wherein 476 cases per 100,000 dog-years at risk were malignant [7]. On the other hand, the incidence of mammary tumors in Sweden is higher and ranges from 111 to 154 per 10,000 dog-years at risk [8].

The incidence of canine mammary gland tumors is related to two main risk factors: age and time of exposure to ovarian hormones [9]. A study performed by Egenvall et al. describes that in bitches at ages 6, 8, and 10 years, the incidence of mammary cancer increased

from 1% to 6% and 13%, respectively [8]. Ovarian hormones (estrogen, progesterone) may lead to carcinogenesis and mammary hyperplasia. Thus, ovariohysterectomy is precautionary for tumor development, and its timing seems to be crucial [10,11]. A female dog of any breed castrated before the first ovarian cycle has a 0.5% chance of developing a tumor. If the bitch is spayed just after or at any subsequent ovarian cycle, the risk of mammary gland cancer increases from 8% to 26% [9,10]. Additionally, the study of Schneider et al. demonstrated that ovariohysterectomy of bitches after their second estrum had no preventive impact against the development of malignant tumors [10].

Canine studies also indicated that obesity is another major risk factor for mammary tumor development, especially if present early in a dog's life [12,13]. The study of Sonnenschein et al. demonstrated that a thin physique reduced the risk of mammary cancer among spayed dogs by 99%, and non-spayed dogs by 40% [12]. The influence of the diet was also studied. Dogs on a homemade diet with high-red meat portions were at a higher risk of developing mammary dysplasia and tumors compared to a commercial diet [13]. Therefore, nutritional factors, operating especially early in life, also have etiological importance to canine mammary cancer (CMC) development.

1.2. Classification System

Mammary glands are a frequent location for tumor development and, as in other types of cancer, canine mammary tumors may be benign or malignant [14]. Since approximately half of mammary tumors in dogs are malignant with a high percentage of mortality if not treated in time, there is no doubt that canine mammary neoplasia represents a serious clinical issue [4,15,16]. Histopathology and biopsy remain the cornerstone and the gold standards for the diagnosis and classification of canine mammary tumors [17]. However, the morphological heterogeneity of these tumors, with frequent presence of various cell populations, is challenging when providing an appropriate classification [17]. Nowadays, veterinary pathologists have available two systems of a histological classification scheme for canine mammary tumors: the official histological classification approved by the World Health Organization (WHO) and the Armed Forces Institute of Pathology from 1999 [18] and the international consensus histological classification scheme based on 2011 updates to the WHO HBC parameters proposed by Goldschmidt et al. from 2011 [19]. The latest 2011 system combines various criteria for subtyping mammary tumors by separating benign forms from malignant lesions and determining the tissue of origin (epithelial, myoepithelial, mesenchymal). A comparison of the two classification systems by Canadas et al. demonstrated that the WHO and 2011 classification systems were very similar in terms of the categorization of benign tumors, and both were prognostically relevant by identifying malignant tumors [17]. Therefore, veterinary pathologists should include both classification systems in the diagnosis and classification of canine mammary tumors.

Based on the tissue of origin, mammary gland tumors of purely epithelial origin are malignant carcinomas, such as carcinoma in situ, simple carcinoma (tubular, tubulopapillary, cystic-papillary, cybriform), solid carcinoma, anaplastic carcinoma, ductal carcinoma, complex and mixed type carcinoma [17,18]. However, there are also other special types of malignant epithelial neoplasms (squamous cell carcinoma, adenosquamous carcinoma, mucinous carcinoma, lipid-rich carcinoma, spindle cell carcinoma, and inflammatory carcinoma) [18,19]. Tubular carcinoma (adenocarcinoma) is the most common type of mammary gland tumor in dogs [19,20]. Mesenchymal neoplasms are sarcomas (osteosarcoma, fibrosarcoma, chondrosarcoma, liposarcoma, hemangiosarcoma, and others), with osteosarcoma as the most frequent mesenchymal neoplasm of the canine mammary glands [19]. However, some of them have mixed histology consisting of a combination of epithelial and myoepithelial or mesenchymal tissue (complex carcinoma, carcinosarcoma, and benign mixed tumors) [19]. Benign mammary tumors are mostly simple and complex adenomas, fibroadenomas, myoepithelioma, ductal adenoma and ductal papilloma [18,19].

The cytology of canine mammary tumors can be another approach in diagnostics, but it should be taken into account carefully, because it offers many false results due to lesions

differentiation, atypic benign forms, and the presence of inflammation or necrosis in the tissue [21,22].

The Nottingham histological grade (NGS), described by Elston and Ellis in 1991 [23], is also used to provide prognostic information by assessing a malignancy score (nuclear pleomorphism, mitotic index, and tubule formation) [23]. In NHG, semi-quantitative evaluation of tubule formation ($\geq 75\%$ of tumor area containing tubules—score I; 10–75% of tumor area containing tubules—score II; $\leq 10\%$ of tumor area containing tubules—score III), quantitative and qualitative judgement of nuclear polymorphism (small nuclei with regular outlines—score I; visible nucleoli and mild nuclei variability in size and shape—score II; severe nuclei variability in size and shape—score III), and mitotic count using a minimum 10 fields of tumor area (≤ 9 mitoses—score I; 10–19 mitoses—score II; ≥ 20 mitoses—score III) [23]. After summing these three component scores, grades from I to III are generated, wherein scores 3–5 indicate a low-grade (I) tumor, scores 6–7 an intermediate (II) tumor, and scores 8–9 a high-grade (III) tumor [23].

1.3. Comparative Oncology

CMC exhibit several similarities with HBC, mainly at the clinical, genetic, molecular, pathological, and etiological levels which are summarized in Table 1 [24]. The clinical correlation between CMC and HBC comprises the onset age, tumor incidence, hormonal etiology, and identical disease course [25]. Interestingly, the average onset age of mammary tumors in dogs (after 6 years) is comparable with the incidence of breast cancer in humans (after 40 years). In addition, the aspects affecting the clinical outcome, such as tumor size, clinical stage, metastasis, and lymph node invasion, are also comparable [26]. Approximately 50% of canine mammary carcinomas are reported to metastasize to regional lymph nodes and lungs, and eventually bones [27,28]. In their human counterpart, almost 20% of HBCs have a prognosis to develop metastatic lesions [29]. Among pathologic characteristics, canine and human tumors share features in a long-term oncogenic environment, intratumoral heterogeneity, and acquired treatment resistance (Table 1) [30]. Markers have the potential to predict the response to a certain anti-cancer treatment [e.g., estrogen and progesterone receptors, cytochrome P450 or antigen Ki-67 for breast cancer; *UGT1A1* gene encoding UDP-glucuronosyltransferase 1-1 enzyme or specific mutations of *K-RAS* (Kirsten rat sarcoma virus), for colorectal cancer; human epidermal growth factor receptor 2, *HER2*, for breast or gastric cancer; *c-KIT* gene encoding tyrosine-protein kinase KIT for gastric cancer; DNA excision repair protein *ERCC1* or tumor protein p53 for lung cancer; reviewed in [31,32]] and provide cancer prognostic information [e.g., antigen Ki-67 or cyclin D1, cyclin E, matrix metalloproteinase-2 (*MMP-2*), protein p21, tumor protein p53, *CD44* or E-cadherin for bladder cancer; beta tubulin for lung cancer; human epidermal growth factor receptor 3 (*HER3*) or inhibitor of growth protein 3 (*ING3*) for melanoma; carcinoembryonic antigen (*CEA*) for colorectal cancer; reviewed in [32]]. Although molecular markers are not routinely used in veterinary medicine, it is not surprising that biomarkers of HBC are also detectable in CMC (Table 1) [26,33]. Specifically, several molecular characteristics, such as up- or downregulation of adhesion molecules (E-cadherin; platelet endothelial cell adhesion molecule-1, *PECAM-1*; carcinoembryonic antigen, *CEA*; mucin 1), overexpression of growth factors (epidermal growth factor receptor, *EGFR*; vascular endothelial growth factor, *VEGF*; epidermal growth factor, *EGF*; insulin-like growth factor-1, *IGF-1*), low or high hormone expression (estrogen, progesterone, prolactin), increased expression of enzymes (metalloproteinase and cyclooxygenase), downregulation of tumor suppressor genes (cyclin-dependent kinase inhibitor 2A, *CDKN2A*; phosphatase and tensin homolog, *PTEN*; breast cancer gene 1, *BRCA1*; breast cancer gene 2, *BRCA2*; and tumor protein 53, *TP53*), up-regulation of oncogenes (*K-RAS*; or mitogen-activated protein kinase, *MAPK*), and elevated production of various proteins (Ki-67 antigen; proliferating cell nuclear antigen, *PCNA*; von Willebrand factor VIII) in CMC mimic HBC (reviewed in [26,33]). A well-known fact is that mutations of *BRCA1* or *BRCA2* tumor suppressor genes contribute to the formation of mammary gland tumors [34]. While the hereditary mutations of these genes have been

observed in humans, no analogous hereditary pattern has been described for mammary cancers in dogs, although Rivera et al. reported a familial risk for mammary cancer in English Springer Spaniel dogs [35]. Etiological factors for mammary cancer development, sex hormones and obesity, are as common for canines as for humans (Table 1). A body mass index (BMI) higher than 25 increased the risk of breast cancer by about 1.3–1.5-fold in women [36]. Similarly, obese dogs at one year of age were more likely to develop mammary tumors [13]. In this background, CMC has been suggested as a spontaneous translational research model to study HBC [37]. Moreover, dogs have several advantages as models of HBC over in vitro cell cultures (e.g., heterogeneity, presence of the immune system, lack of cross-contamination or cell line instability) and rodent models (e.g., genetic diversity, intact immune system, larger body size and blood volume, long-term monitoring, and the same environment as humans) [37,38]. Despite these similarities, CMC and HBC have some histological discrepancies [19,20,39]. For example, benign tumors are more prevalent in CMC than in HBC [20]. Further, mammary tumors with a mesenchymal origin (fibrosarcomas) and mixed histology (carcinosarcomas or complex carcinomas) are often diagnosed in female dogs and are very rare in humans [19]. Instead, the most common type of mammary tumors in humans is the invasive ductal carcinoma [39].

Table 1. Comparison of canine mammary cancer and human breast cancer.

Correlation Level	Similarities
clinical	onset age tumor incidence clinical stage metastasis lymph node invasion hormonal etiology disease course
pathological	long-term oncogenic environment intratumoral heterogeneity treatment resistance
molecular	up- or downregulation of adhesion molecules overexpression of growth factors low or high hormone expression upregulation of oncogenes downregulation of tumor suppressor genes elevated production of various proteins altered microRNA expression
etiologial	sex hormones obesity

1.4. Treatment

Even though the improved health of dogs, as a result of better quality and more easily reachable veterinary care, treatment, and better nutrition, allows dogs to live longer, the incidence of cancer in dogs is constantly increasing [20]. Surgery consisting of the removal of the affected (cancerous) glands and local lymph nodes is currently the only efficient treatment and can be curative in many dogs [40,41]. In malignant cases, chemotherapy and radiotherapy are applied [33,42]. However, this aggressive approach is expensive and limited, with no definitive data [33,42]. No protocol for chemotherapy in female dogs affected by mammary gland tumors has thus far been standardized [41]. In addition, chemotherapy in dogs has not been proven to be as effective in the treatment of mammary gland cancers as it is in women [42,43]. Standard chemotherapeutics, such as docetaxel and doxorubicin, have not demonstrated dramatically improved overall survival times [44]. Thus, at this time, no effective systemic treatment options for dogs with mammary tumors are available. Because of the limited treatment possibilities, early diagnosis of cancer,

evaluation of the cancer progression, and tumor response to chemotherapy can increase the survival of dog patients. Biomarkers represent a valuable tool in cancer research since they offer many applications, such as screening, differential diagnosis, prognosis determination, prediction to treatment, and disease progression monitoring [45,46].

2. MicroRNAs as Potent Biomarkers

A biomarker is generally defined as a quantifiable measure of a normal biological process or pathological process or as a response to a therapeutic administration [47]. In other words, a biomarker offers information about the actual condition of a living organism. Changes in biomarkers expression levels, concentrations or structure may indicate the onset, progression or regression of some disorder in the body [48]. Biomarkers can be represented by nucleic acids (DNA or RNA) [49], peptides [50], proteins [51], lipids [52] or metabolites [53].

MicroRNAs (miRNAs or miRs) are becoming potential non-invasive cellular and molecular biomarkers for the prediction, diagnosis, prognosis, and therapeutic targets for various types of cancers. Several studies have thus far confirmed the relevance of miRNAs in cancer-associated processes, including proliferation, differentiation, invasion, angiogenesis, metastasis, apoptosis, and drug resistance (reviewed in [54–57]).

2.1. Biogenesis and Function

miRNAs are short (18–22 nucleotides), highly evolutionary conserved members of small non-coding RNAs discovered in 1993 in a model organism *Caenorhabditis elegans* [58,59]. The miRNA arises as a transcription product of non-coding regions or introns by RNA polymerase II [60]. Still in the nucleus, the resulting hundreds of nucleotides long primary miRNA (pri-miRNA) is subsequently cleaved by the endonuclease enzyme Drosha (RNase III) and its cofactor microprocessor complex subunit DGCR8 (DiGeorge syndrome critical region gene 8, also known as Pasha), giving the precursor miRNA (pre-miRNA) [61]. Pre-miRNA has a hairpin and loop-shaped secondary structure with 80–100 nucleotides [62,63]. This pre-miRNA is transported from the nucleus into the cytoplasm by the exportin-5 protein and the Ran-GTP complex [64]. Here, the hairpin region of the pre-miRNA is processed by cytoplasmic ribonuclease Dicer into an 18 to 22 nucleotide long double-stranded miRNA duplex which contains two 5' phosphorylated sequence strands with 3' overhangs, named the mature miRNA guide strand and complementary passenger strand [65,66]. The miRNA duplex is unwinded into a single-stranded mature miRNA guide strand (depicted with black color in Figure 1), while the second passenger strand is degraded (depicted with red color in Figure 1) [67,68]. The mature miRNA strand binds to Argonaute 2 (Ago2) protein and other RNA-binding proteins (e.g., protein kinase RNA activator, PACT; trinucleotide repeat-containing gene 6A protein, TNRC6A; transactivation response RNA-binding protein, TRBP) to form an RNA-induced silencing complex (RISC) that regulates the translation of target messenger RNA (mRNA) [67]. In addition to the transcription repression within the cell, the mature miRNA can be also secreted from the cell as free (circulating) miRNA or intracellularly packed into the extracellular vesicles (EVs), such as exosomes (or small extracellular vesicles, sEVs) or microvesicles (or medium/large extracellular vesicles; m/IEVs) [69,70]. Mature miRNAs are selectively incorporated into the sEVs (exosomes) or enwrapped with microvesicles during their biogenesis (in process of early endosome inner membrane budding), as explained in Section 3.1, and subsequently, released to the extracellular milieu [70]. Such EV-packed miRNAs are delivered, through the EVs, to other target cells, where the miRNAs regulate their cognate target genes at the transcriptional level [69,71–74]. Within the cell, mature miRNAs are associated with RNA-binding proteins, such as Ago2, which protect free miRNAs from degradation by RNases after their release from the cells to the extracellular environment [75]. Free miRNAs are presented in different biofluids (such as blood plasma or serum [76,77], urine [78], breast milk [79], saliva [80], tears [81], or cerebrospinal fluid [82]) [75]. However, the precise mechanism of how free miRNA is released from cells is still not clear [69,70]. The process of miRNA biogenesis is summarized in Figure 1.

The miRNAs play a key role as negative post-transcriptional gene regulators in the safeguarding of all biological processes of multicellular organisms, including cell-cycle control, cell proliferation, differentiation, migration, metabolism, and apoptosis [83]. Regulatory action is mediated by the hybridization of miRNA to the 3'- or 5'-untranslated regions (UTRs) [84,85], or the open reading frame (ORF) [86] of the target mRNAs, resulting in the suppression of the expression of the protein-coding genes either by translational repression, mRNA degradation or both [87,88]. More specifically, perfect base complementarity leads to mRNA degradation, while non-perfect (partial) base complementarity results in translation impairment [89].




Figure 1. Biogenesis and release of microRNA (miRNA) and exosomes. The miRNA initially originates as primary miRNA (Pri-miRNA). Pri-miRNA is cleaved into the precursor miRNA (Pre-miRNA) by the Drosha enzyme and its cofactor Pasha [61,62]. Exportin-5 protein and Ran-GTP complex transport the pre-miRNA into the cytoplasm, where it is processed into the double-strand miRNA duplex by the action of a Dicer endonuclease [64–66]. One of the strands is degraded (so-called passenger strand; depicted with red color) and the second, mature miRNA strand (also known as guide strand; depicted with black color) is loaded into the RNA-induced silencing complex (RISC) by the binding to RNA-binding proteins (Argonaute 2, Ago2; trinucleotide repeat-containing gene 6A protein, TNRC6A; transactivation response RNA-binding protein, TRBP) [67,68]. The mature miRNA strand is then guided to the target messenger RNA (mRNA) to either degrade (perfect base complementarity) or inhibit the mRNA translation (partial base complementarity) [89]. The mature miRNA can be also secreted from the cell as free miRNA bound to RNA-binding proteins or incorporated, within the cell, into the extracellular vesicles (EVs), specifically exosomes and microvesicles [69,70]. Exosomes or small extracellular vesicles (sEVs; <200 nm) [90] are produced within the cells starting with the formation of early endosomes by cell membrane invagination [91–93]. The inner membrane budding of the early endosome leads to the maturation of the multivesicular bodies (MVBs) [91–93]. Some of MVBs are directed to lysosomes for degradation, while others are released to the extracellular space as exosomes after fusion with the plasma membrane [94,95]. Microvesicles or medium/large extracellular vesicles (m/IEVs; >200 nm–1000 nm) [90] are formed in the process of outward plasma membrane budding [96,97]. Apoptotic bodies (>1000 nm), the largest group of EVs, are released from the cells undergoing apoptosis by plasma membrane blebbing [90,98,99]. An original figure was created using Inkscape v1.1.2 software.

2.2. The Role of miRNAs in Cancer

Since gene regulation at the transcriptomic level does not require the high complementarity of miRNA with the mRNA sequence, a single miRNA may target several mRNAs, and aberrant miRNA expression has the potential to considerably alter the expression level of several hundred transcripts [100,101]. Dysregulation of miRNAs is particularly prevalent in cancer, where the genetic instability of tumors (such as amplifications, deletions, mutations, epigenetic changes or polymorphisms) leads to altered miRNA expression profiles promoting oncogenesis [102,103]. Downregulated and deleted miR-15a and miR-16-1 in patients with chronic B-cell lymphocytic leukemia were firstly reported as altered miRNAs, leading to the onset, progression, and dissemination of cancer [104]. Subsequently, the interface between overexpression or ablation of miRNA and cancer development was exhibited in mouse models [102,105]. Nowadays, it is known that more than half of miRNAs are located in cancer-associated genomic regions [106]. Generally, miRNAs involved in cancer are either tumor suppressors or oncogenes, depending on the expression levels [107]. Overexpressed miRNAs, oncogenes, with a crucial role in the initiation and progression of cancer, have been termed oncomiRs [108]. As of February 2022, more than 40,000 free-full peer-reviewed articles dedicated to the investigation of the role of miRNA in cancer by diverse experimental approaches are available in the PubMed depository (<https://pubmed.ncbi.nlm.nih.gov/?term=mirna+cancer&filter=simsearch2.ffrft> (accessed on 1 February 2022)).

2.3. Non-Exosomal miRNA-Based Biomarkers of Canine Mammary Cancer

As of February 2022, 502 precursors and 453 mature miRNAs have been identified in the canine genome (miRBase database; <https://www.mirbase.org/summary.shtml?org=cfa> (accessed on 1 February 2022)) and most of them have been altered in CMC. As was discussed above, CMC and HBC demonstrate comparable clinical and pathological characteristics. Similarities in the miRNA expression pattern between canine mammary and human breast neoplasia have also been described [109] and several oncomiRs have been found to be highly conserved between dogs and humans [110,111]. These findings are not surprising, since dogs and humans share not only the same environment but also analogous diseases [112]. Moreover, considering the similarities between dogs and humans at the genetic level, miRNAs may target genes conserved between both. Aberrant expression of miRNAs implicated in cancer development, progression or metastasis may serve as a useful biomarker for diagnostic or prognostic purposes and, therefore, represent a target for therapy development [102].

Here, we review the most relevant miRNAs not packed into exosomes (hereinafter called non-exosomal) found in CMC studies in relation to the biomarkers for future clinical applications and compared their incidence in HBC. We found 11 articles related to the topic. According to the analysis carried out for this review, here the term “non-exosomal” is referred to miRNAs which come from sources such as mammary tumors [110,111,113–115], tumor mammary cell lines [116–118] or canine blood serum [119–121] using commercial kits.

The first study of miRNAs expression in CMC from 2008 investigated the expression levels of HBC key miRNAs (miR-15a, miR-16, miR-17-5p, miR-21, miR-29b, miR-125b, miR-145, miR-155, miR-181b, let-7f) in relation to CMC. Boggs et al. revealed that, apart from miR-145, the monitored miRNAs proved to have the same expression pattern as observed in humans [110]. The miR-15a and miR-16 show a significant downregulation in canine ductal carcinomas, while miR-21, miR-29b, miR-181b, and let-7f were upregulated in tubular papillary carcinomas. Mainly, miR-21 and miR-29b demonstrated statistically significant ($p < 0.05$) upregulation in canine tumor samples [110].

2.3.1. miR-21

It is assumed that overexpression of miR-21 is a hallmark of carcinogenic cells and may serve as a common signal of pathological growth or cell stress [122]. The miR-21 is highly conserved and one of the most abundant miRNAs expressed in multiple mammalian

cell types [122,123]. Physiologically, miR-21 regulates processes connected to cell growth, migration, and invasion [124]. In carcinogenesis, miR-21 acts as the oncomiR through the inhibition of tumor cell apoptosis [110,125,126]. Except in the study of Boggs et al. [110], the upregulated expression of miR-21 in canine benign or malignant tumors in comparison to normal glands was observed in several canine mammary studies [113–115,119,120]. The elevated expression of miR-21 in female dogs with mammary tumors is in correlation with progressive clinical stage and poor prognosis [119]. Thus, the level of miR-21 expression may be useful for distinguishing between bitches with mammary tumors (benign or malignant) and healthy ones (without mammary tumors) [119]. Moreover, increased expression of miR-21 in metastasis carcinoma (5.05-fold) compared to normal mammary gland makes it a good metastasis biomarker [114]. Regarding HBC, the altered expression of miR-21 was associated with increased cell proliferation, colony formation, migration, invasion, metastasis, angiogenesis, advanced tumor stage, lymph node metastasis, and poor patient survival [127–132]. Blocking miR-21 expression inhibits tumor growth and metastasis [133]. As miR-21 is one of the most upregulated miRNAs in HBC, it was postulated that targeting miR-21 by miR-21 inhibitors (anti-miR-21) as post-transcriptional gene silencing agents may have a therapeutic potential [134–136]. It follows that miR-21 represents a sensitive non-invasive biomarker for cancer screening, progression, and detection in CMC as well as in HBC.

2.3.2. miR-29b

Another non-invasive biomarker for diagnostic and prognostic purposes for various types of cancer, including mammary cancer, can be miR-29b [137,138]. As a member of the miR-29 family together with miR-29a and miR-29c, miR-29b appears to have a crucial effect on mammary tumors by regulating multiple cancer-related processes essential for tumor development, such as proliferation, apoptosis, metastasis, fibrosis, angiogenesis, proteolysis or collagen remodeling [139]. However, the exact role of miR-29b in cancer remains controversial, as it has been declared as an oncomiR and tumor-suppressor [138–142]. The differential expression of miR-29b has also been noted in CMC. Together with the study of Boggs et al. [110], the upregulated expression of miR-29b was observed in canine SNP cell line (4.0714-fold) [116] or serum samples from canine mammary carcinoma dogs (2.78-fold) [121]. In contrast, a significant downregulation of miR-29b expression in metastasizing and non-metastasizing mammary tumors was observed in the studies of Jain et al. [119], Bulkowska et al. [113], and von Deetzen et al. [114]. Due to the altered expression of miR-29b in a metastatic group in comparison with benign tumors, miR-29b may present another valuable biomarker for metastasis [113]. An inconsistent downregulated [143] or upregulated [144] expression pattern of miR-29b was also observed in HBC, wherein this was connected with proliferation, migration, impaired apoptosis, increased tumor cell migration, and invasion.

2.3.3. miR-141

The very first evidence of comprehensive expression profiles of the 277 investigated miRNAs from the canine genome, which were evaluated using a quantitative polymerase chain reaction strategy in cell lines derived from female dogs of different breeds with spontaneous mammary carcinomas or adenocarcinomas (CMT12, CMT27, and CMT28), revealed miR-141 to be a potent oncomiR [117]. In this study, miRNA-141, a member of the miR-200 family, was experimentally validated to target 3'-UTR of a tumor suppressor INK4 (inhibitor of CDK4), a member of the INK4/CDNK2 family of tumor suppressor genes, through the direct correlation between the overexpression of miR-141 and the target mRNA p16/INK4A in cell lines CMT12 and CMT27 [117]. Significant high expression levels of miR-141 are strongly associated with highly aggressive breast carcinomas (grade III) when compared to grade II breast cancer. ROC curve analysis revealed the diagnostic and prognostic utility of miR-141 in the discrimination of malignant from benign breast tissues (ROC-AUC = 0.97). Moreover, high expression of miR-141 is associated with worse overall survival (OS) in breast cancer patients (HR = 1.43, 95% CI = 1.17–1.74, $p = 0.00037$;

among 1262 patients) [145]. Additionally, upregulation of miR-141 promotes the migratory and invasive abilities of an aggressive triple-negative breast cancer cell line MDA-MB-231 through regulation of the phosphatidylinositol-4,5-bisphosphate 3-kinase/protein kinase B (PI3K/AKT) signaling pathway by increased secretion of vascular endothelial growth factor A (VEGF-A) and expression of integrin- α V [146]. Together, all these data highlight the role of miR-141 as a valuable biomarker with potential clinical applications in CMC as well as HBC.

2.3.4. miR-429 and miR-200c

The study of Lutful Kabir et al. reported another group of miRNAs to be altered in both canine mammary and human breast tumors [117]. The miR-9, miR-155, miR-200a/b, and miR-429 were overexpressed, whereas miR-1, miR-133a/b/c or miR-214 were found to be downregulated in canine cell lines CMT12, CMT27, and CMT28 [117]. In particular, miR-429 and miR-200c were found to be highly upregulated (>1000 fold and 100–150 fold, respectively) and predicted to target the tumor suppressor ERBB receptor feedback inhibitor 1 (ERRFI1) mRNA [117]. Thus, both miRNAs act as oncomiRs in CMC [117]. Comparable to HBC, miR-429 was also described as an oncomiR that affects the hypoxia-inducible factor 1-alpha (HIF1 α) pathway by targeting VHL mRNA [147]. The overexpressed miR-429 in breast cancers with amplified human epidermal growth factor receptor 2 (HER2+) was responsible for the increased proliferation and migration of breast cancer cells, while the silencing of miR-429 had an impact on tumor growth postponement [147]. In contrast, miR-200c was reported as a tumor suppressor in breast cancer tissue and cell lines where suppress the cell proliferation by targeting KRAS mRNA [148], contributes to the paclitaxel resistance by targeting (sex-determining region Y)-box 2 (SOX2) transcriptional factor [149], or inhibits the metastasis of triple-negative breast cancer [150]. Since both miRNAs are involved in the tumorigenesis and progression of a variety of cancers, they may represent potent biomarkers in CMC and HBC.

2.3.5. miR-497

Tumor-suppressor miR-497 family members (miR-497, miR-195, miR-15, and miR-16) were found to be downregulated in canine mammary cell lines [118]. Downregulation of miR-497 was also observed in the CMT1211 and CMT7364 cell lines compared to primary canine mammary gland cells [118]. Transfection of miR-497 mimic and inhibitor into the canine mammary tumor cells showed that overexpression of miR-497 significantly inhibited cell proliferation and migration, and increased the apoptosis in the CMT1211 and CMT7364 cell lines [118]. The observed negative correlation between miR-497 and the expression of interleukin-1 receptor-associated kinase-like 2 (IRAK2) suggested IRAK2 as a functional target gene of miR-497. The suppression of IRAK2 mRNA by the overexpressed miR-497 induced apoptosis by inhibiting the activation of the pro-survival NF- κ B (nuclear factor kappa-light-chain-enhancer of activated B cells) pathway [118]. This study demonstrated that miR-497 inhibits cancer cell growth, with the suggestion of the miR-497/IRAK2/NF- κ B axis as a potential mechanism for CMC development [118]. Therefore, miR-497 was suggested as a diagnostic biomarker and therapeutic target in CMC [118]. These findings are consistent with HBC, where miR-497 was among the most prominently downregulated miRNAs [151]. Several studies have demonstrated that overexpression of miR-497 inhibited the proliferation, invasion, metastasis, angiogenesis or cell cycle of cancer cells, and induced apoptosis in HBC by targeting Bcl-2-like protein 2 (Bcl-w) [152], B-cell lymphoma 2 protein (Bcl-2) [153], yes-associated protein 1 (YAP1) [154], HIF-1 α [155], or cyclin E1 [156] mRNA.

2.3.6. miR-10b, miR-101, miR-125a/b, miR-136, miR-143, miR-145, let-7f, and miR-203

Several miRNAs demonstrated a more important role in the metastasis process than in the malignant transformation. Downregulated miR-10b, miR-101, miR-125a/b, miR-136, miR-143, miR-145, and let-7f, as well as upregulated miR-203 were found in a metastatic group in comparison with non-metastasizing or benign canine mammary tumors [113,114].

The expression levels of miR-10b, miR-125b, miR-136, and let-7f in particular gradually decreased from normal mammary tissue, through benign tumors and non-metastatic malignant tumors, to metastatic tumors [113]. These findings are of great predictive importance for the course of a disease and, therefore, altered miRNAs may constitute molecular markers of metastasis.

On the other hand, the expression level of miR-143 in non-metastasizing mammary carcinoma [114] or the canine SNP cell line established by Osaki et al. [116] was higher in comparison to normal mammary gland tissue (2.70-fold and 1547.9-fold, respectively). Likewise, miR-203 expression was downregulated in benign tumors compared to a healthy control group [113]. Such discrepancies in the expression level of one particular miRNA may be a result of changes in gene expression in the tumor, different tumor phenotypes or even different data analyses used to evaluate miRNA expression [113].

2.3.7. miR-210

Some miRNAs are expressed at different stages of malignancy [114]. For example, miR-210 was found to be present in malignancies, such as adenoma, non-metastasizing carcinoma, metastasizing carcinoma, and metastatic tissue with gradually increased expression (7.01-fold, 10.41-fold, 10.72-fold, and 19.63-fold respectively) [114]. As explained by the authors of the study, miR-210 has been termed a hypoxamir due to its upregulation as a result of hypoxia in tissues and it mediates the metabolic adaptation to anaerobic conditions [114,157]. Therefore, rising expression during the progression of malignancy may be a result of increased hypoxia in tumor growth. Since miR-210 is associated with the formation of capillary-like structures [158], the author also hypothesized its role in metastasis by enhanced angiogenesis. This makes miR-210 another potential diagnostic marker in malignancies [114]. Higher expression of miR-210 in canine neoplasms than in a control group was also observed in the study of Bulkowska et al. [113]. In HBC tissue, overexpression of miR-210 correlates with lymph node metastasis, clinical staging, differentiation and poor prognosis in patients with breast cancer. Therefore, miR-210 was proposed as a potential prognostic biomarker of breast cancer [159,160].

2.3.8. miR-138a

Among 18 significantly decreased miRNAs in the canine SNP cell line, miR-138a showed the greatest reduction in the expression (0.007-fold) [116]. As discussed in this study, tumor-suppressive miRNA-138a represses the epithelial-mesenchymal transition (EMT), a process resulting in cancer aggressiveness and metastasis. Since this study showed that some SNP cells were positive for vimentin as an important EMT marker [161], the authors declared that SNP cells undergo the EMT process, which also confirms the suppressive and biomarker role of miR-138a in CMC [116].

2.3.9. miR-8832, miR-96, and miR-149

Genome-wide methylation profiling in canine mammary tumors revealed miR-8832 as a new miRNA associated with both CMC and HBC [111]. Downregulated *GNAO1* (guanine nucleotide-binding protein-alpha O1) in canine mammary tumors was predicted as its target gene. As discussed by the authors, this tumor suppressor gene is involved in the reduction of cell proliferation in some human cancers, and dysregulation of *GNAO1* mRNA may be involved in tumorigenesis. Thus, miR-8832 represents a potential biomarker in both canines and humans [111].

The study also identified other miRNA candidates, upregulated miR-96 and downregulated miR-149, reported as cancer-associated miRNAs in humans [111]. Oncogenic miR-96 was found to be constantly upregulated in breast cancer tissues where it promotes proliferation, migration, and the invasion of cancer cells through silencing the target gene *PTPN9* (gene for tyrosine-protein phosphatase non-receptor type 9) [162]. Tumor-suppressive miR-149 contributes to breast tumor progression by supporting aberrant Rac activation [163] and recruitment of macrophages to the tumor [164]. Using the sequence-based target prediction

program TargetScan, the authors predicted *BRPF3* (gene encoding a bromodomain and PHD finger containing 3), *ADCY6* (gene encoding adenylyl cyclase type 6), and *LRIG1* (gene encoding leucine-rich repeats and immunoglobulin-like domains protein 1) as targets for miR-96, and *RNF2* (gene encoding E3 ubiquitin-protein ligase RING2) as a target for miR-149, highly conserved genes in dogs and humans [111].

Generally, miRNAs are more stable (up to 10-times) than mRNAs [165,166] and easy to detect in samples, such as tissues obtained from biopsy or surgery or biological fluids (such as serum, plasma, urine, saliva, seminal, ascites, amniotic pleural effusions, or cerebrospinal fluid) [167]. However, invasive procedures, such as tissue sample collection, are not very suitable for diagnostic or screening purposes, as mammary biopsies may yield a very small amount of RNA, with differences in quantified miRNAs at the level of one nucleotide [110]. In this regard, feasible and relatively non-invasive biofluid-extracted circulating miRNAs have attracted interest in the term of biomarkers as novel diagnostic tools for cancer, as this would limit the need for the collection of tissue samples and other invasive procedures [168]. Except for simple isolation, circulating miRNAs maintain stability under different conditions of sample processing and isolation [169]. Circulating miRNAs, as well as intracellular miRNAs, are also involved in the regulation of several biological processes with abnormal expression during pathological conditions [170]. Altered expression of circulating miRNAs is related to the initiation and progression of cancer [170]. Biofluid miRNAs show dynamic changes in physiological and pathological states before the clinical signs appear [171]. Furthermore, importantly, circulating miRNAs can be easily detected by basic molecular techniques [170]. Several circulating miRNAs have been described as biomarkers in cancer, including HBC (reviewed in [170,172]). Based on a literature review, we found four studies investigating levels of circulating miRNAs in plasma or serum samples in canine mammary tumors [113,119–121]. Nonetheless, the first study by Bulkowska et al., comparing differences between metastatic and non-metastatic tumors, showed no significant differences in the expression of selected metastasis-specific miRNAs (*cfa-miR-144*, *cfa-miR-32*, *cfa-miR-374a*, and *hsa-miR-1246*) by polymerase chain reaction (PCR) analysis [113]. On the other hand, the recent study by Fish et al. revealed circulating miRNAs as biomarkers of canine mammary carcinoma [121]. In this work, serum miRNA from 10 healthy female dogs and 10 bitches with histologically confirmed mammary carcinoma revealed 452 unique serum miRNAs by RNA deep-sequencing and 65 miRNAs differentially expressed ($>\pm 1.5$ -fold) and statistically significant between groups (carcinoma vs. healthy) by digital droplet PCR (dPCR). Although the expression of several miRNAs, such as miR-29b, miR-34c, miR-122, miR-125a, and miR-181a, was found to be upregulated, the authors suggested differentially expressed circulating miR-18a and miR-19b as the most potential biomarkers.

2.3.10. Circulating miR-18a

Significantly upregulated serum miR-18a (1.94-fold by RNA sequencing; 1.24-fold by dPCR) was suggested as a candidate prognosis biomarker for CMC [121]. The authors revealed significantly higher levels of miR-18a in the group with histologic evidence of lymphatic metastasis invasion than without (2.82 versus 1.23 reads per million). Thus, miR-18a was proposed as a strong candidate prognostic biomarker also for HBC risk [121]. Circulating miR-18a was also overexpressed in a set of 60 serum samples from women with early-stage breast cancer compared to a sample of 51 healthy controls, suggesting miR-18a as a blood-based multi-marker for the early detection of HBC [173]. Generally, miR-18a, a member of the miR-17-92 cluster, suppresses the translation of estrogen receptor α (ER α), thus decreasing the protective effect of estrogen [174]. This finding was also observed in breast cancer-derived cell lines MCF-7 and MDA-MB-231, wherein not only the low expression of the ER, but also a decreased sensitivity to tamoxifen, and endocrine resistance, was associated with miR-18a high expression [175]. In another study, the overexpression of miR-18a in breast cancer cell lines MCF7 and ZR-75-1 led to an increase in the cells' proliferation and migration, significant repression of E-cadherin, activation of genes of the Wnt (Wingless and Int-1) noncanonical pathway, PCP (planar cell polarity) pathway,

JNK (c-Jun N-terminal Kinase) pathway, and actin remodeling [176]. Furthermore, miR-18a was suggested as an early driver of tumorigenesis, since it was found to be upregulated in contralateral unaffected breasts and benign biopsy samples before the development of breast cancer [177].

2.3.11. Circulating miR-19b

Another significantly upregulated (3.15-fold by RNA sequencing; 1.76-fold by dPCR) serum miR-19b was proposed as a candidate diagnostic biomarker [121]. The ability to distinguish between mammary tumor-bearing dogs and dogs without neoplasia based on miR-19b was also revealed in this study with the ROC-AUC (receiver operator characteristic-area under the curve) and sensitivity/specificity analysis (ROC-AUC = 0.978) [121]. The miR-19b is a key molecule for cancer development, as it was found to be an active participant in the pathogenesis of various types of cancer, including HBC [178,179]. In breast cancer studies, miR-19b has demonstrated tumor-promoting activities. The wound-healing assay and transwell invasion assay performed by Zhao et al. demonstrated that overexpressed miR-19b facilitated the migration and metastasis of breast cancer cells by downregulation of myosin regulatory light chain interacting protein (MYLIP) involved in the regulation of cell movement and migration [179]. In the same study, miR-19b promoted the downregulation of E-cadherin and upregulation of intercellular adhesion molecule 1 (ICAM-1), and Integrin β 1 in vitro and in vivo, leading to the activation of downstream signaling pathways (the Ras-MAPK pathway and the PI3K/AKT pathway) and involved genes [179]. In another study, miR-19b was found in less invasive breast lines (MCF-7, T47D, and ZR-75-1 cells) as well as in invasive breast lines (MDA-MB-231 and BT-20 cells), wherein it regulated at a post-transcriptional level the expression of tissue factor, known as a regulator of tumor angiogenesis and metastasis [178]. Taking together the results of these studies, miR-19b serves as an oncomiR in the progression of breast cancer and could act as a biomarker.

2.3.12. Circulating miR-21 and miR-29b

The latest studies from 2021 investigated serum miRNA-based biomarkers, miR-21 and miR-29b. Both miRNAs were also altered in tumor samples, as discussed above. In the study of Jain et al., serum samples of 60 female dogs (20 healthy/control, 20 with benign tumors, and 20 with malignant mammary tumors) were used [119]. Serum miR-21 was upregulated in malignant (3.0-fold) and benign (1.8-fold) tumors compared to the control samples (1.1-fold), while the expression of serum miR-29b was significantly downregulated in the malignant and benign group compared to the control samples (0.2-fold, 0.4-fold, and 1.1-fold, respectively). Interestingly, the expression was higher/lower in malignant tumors than in benign tumors. As suggested by the authors, circulating miR-21 could serve as a prognostic marker for the early detection of canine mammary tumors, and miR-29b can add sensitivity and accuracy to a diagnosis if evaluated together with miR-21 [119]. In the study of Ramadan et al., miR-21 was significantly upregulated (12.84-fold) in the serum samples of 10 female dogs with mammary tumors compared to the control group of 7 healthy bitches. Thus, miR-21 was hypothesized as a more sensitive, non-invasive indicator for CMC [120]. These observations are in accordance with other studies on tumor samples [110,113,114].

Despite the above-mentioned advantages of circulating miRNAs as biomarkers (non- or minimally invasive availability and easy accessibility, stability or resistance toward severe stressing conditions, such as high temperatures, repeated freeze–thaw cycles), they still have several issues hindering their reliability for the clinical application [180]. One of the major limitations of circulating miRNAs as biomarkers is the inability to identify their exact origin [181]. For example, most circulating miRNAs are obtained from blood using plasma or serum as the source [181,182]. However, blood contains a variety of cell types that challenge the identification of the cell origin of a particular miRNA [181]. The majority of the miRNAs in the blood are packaged in EVs like microvesicles (or m/IEVs) and exosomes (or sEVs) [180]. Exosomes and exosome-derived miRNAs have attracted great

attention in recent years in terms of biomarkers [183]. A literature review of miRNAs from exosomal and non-exosomal sources showed that 71% of the selected articles concluded that exosomes are the source of choice for miRNAs in biomarker studies. In addition, 75% of articles comparing both sources of miRNAs recommended exosome-derived miRNAs over non-exosomal miRNAs [181]. Thus, it can be assumed that exosomes can be a better source of miRNAs as biomarkers due to their benefits in terms of quantity, quality, and stability [181], as discussed below.

3. Exosomes

3.1. Nomenclature

The International Society for Extracellular Vesicles (ISEV) approves the definition of EVs as lipid bilayer-surrounded particles released from the cell without the ability to replicate. Due to intersecting characteristics and the lack of consensus on specific markers of different EV subtypes (e.g., expression of CD9, probable marker of exosomes and ectosomes; [184]), some authors suggested rather to consider the origin of EVs. Based on this, the term exosomes should refer to the intracellular compartment-originated EVs and ectosomes (microparticles/microvesicles) as EVs derived from the plasma membrane [185,186]. However, the EVs' designation to a particular biogenesis pathway is challenging. Therefore, the ISEV proposed in 2018 "Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines" as recommendations for EVs nomenclature [90]. In total, 94% of MISEV2018 respondents affirm the classification of EVs subtypes according to either (i) physical characteristics such as size ("small EVs"; sEVs (<100 nm or <200 nm) and "medium/large EVs"; m/IEVs (>200 nm)) or density (low, middle, high), (ii) biochemical composition of surface markers (e.g., CD63+ EVs, CD81+ EVs, CD81- EVs, CD9+ EVs) or (iii) origin of parental cell or biological processes (e.g., tolerosomes, oncosomes, apoptotic bodies) [90]. However, the reviewed literature does not take into account the MISEV2018 guidelines and keeps the term "exosomes". To avoid misunderstanding in this review we decided to keep both terms "exosomes" and "sEVs".

3.2. Biogenesis

Since the identification of exosomes in sheep reticulocytes in the 1980s [187,188], these small endosomal-derived membrane vesicles have gained high interest over the last decade. sEVs (exosomes) are a subset of EVs secreted into the extracellular space by prokaryotic and eukaryotic cells, as well as in physiological and pathological processes [189]. To distinguish them from other EVs excluded from the body fluids, Rose Johnstone and colleagues gave them the name exosomes [190], now called sEVs based on the MISEV2018 guidelines [90]. As was described above, EVs are generally categorized based on their size into sEVs or m/IEVs [90]. Microvesicles (also known as ectosomes, microparticles or m/IEVs) have typically a diameter of medium/large-sized EVs (>200 nm–1000 nm) and are formed in the process of outward plasma membrane budding [90,96,97]. The suggested protein markers are CD40, selectins, and integrins [191]. Whereas sEVs (exosomes) and m/IEVs (microvesicles) are secreted during normal cellular processes, apoptotic bodies (>1000 nm) are only formed and released from the cells undergoing programmed death by plasma membrane blebbing [98,99] and express phosphatidylserine, the so-called "find-me, eat me" signal that triggers macrophage clearance [192–194]. Apoptotic bodies differ from the other two major EV groups by containing fragments of host DNA and cellular organelles [193]. These EVs can be distinguished by protein markers, such as histones, thrombospondins, and C3b [195]. sEVs (exosomes) are nano-sized (<200 nm) EVs surrounded by a lipid bilayer membrane which is characteristic for all EVs and protects the encapsulated material, such as nucleic acids (DNA, mRNA, and non-coding RNAs), proteins, peptides, chaperons, lipids, metabolites, from the extracellular environment (Figure 2) [191,196]. Other authors subclassify the sEVs (exosomes) based on the size into exomeres (35 nm), small exosomes (Exo-S) (60–80 nm), and large exosomes (Exo-L) (>90 nm) [197]. sEVs (exosomes)

are produced within the cells by an endocytic pathway regulated by proteins and lipids in form of the multivesicular bodies (MVBs) and released to the intercellular space after fusion with the cell membrane [94]. Shortly, sEV (exosome) maturation begins with the formation of the early secretory endosome mediated by clathrin- or caveolin-dependent or independent invagination of the cell membrane, together with the accumulation of bioactive substances [91–93]. The budding of the inner membrane of early endosomes leads to the maturation of the MVBs [91–93]. During this process, some proteins are incorporated into the invaginating membrane, while the cytosolic components (such as nucleic acids, protein, chaperones, peptides, metabolites, and lipids) are enclosed inside (Figure 2) [198]. MVBs are late endosomes containing intraluminal vesicles. MVBs are of two destinies: (1) direction to the lysosome for degradation by enzymes in the lysosome lumen; or (2) fusion with the plasma membrane to release the content (i.e., intraluminal vesicles) into the intercellular space (Figure 1) [94,95]. The factors determining the direction of MVBs are still poorly known [199]. However, it was found that secreted MVBs contain an important pool of cholesterol [200]. This observation raises the question of whether high levels of cholesterol may be the determining parameter of MVBs' destiny. Most of the released intraluminal vesicles are sEVs (exosomes). The biogenesis of MVBs, together with exosome formation and release, is mediated by endosomal sorting complexes required for transport (ESCRT) mechanism and other ESCRT-associated proteins (vesicle trafficking 1, VTA1; apoptosis-linked gene 2-interacting protein X, ALIX; tumor susceptibility gene 101 protein, TSG101; or vacuolar protein sorting-associated protein; VPS4) [201–203]. The ESCRT is complex machinery that comprises four different types of multiprotein sub-unit complexes, named ESCRT-0 to III. ESCRT-0 is responsible for the recognition and recruitment of ubiquitinated cargo to the endosomal membrane, ESCRT-I and II for the membrane budding, and ESCRT-III mediates vesicle separation from the plasma membrane [204]. Additionally, recent evidence has demonstrated the effect of ESCRT-independent pathways on exosome formation [205–207]. It can be assumed that exosome formation is controlled by factors in the cell and tissue microenvironment [97,208–210]. On the one hand, the production of sEVs (exosomes) is cell-regulated, as needed [97]. On the other hand, cell stress factors (hypoxia, acidosis) [208,209] or stimulation by growth factors (epidermal growth factor) [210] were found to induce exosome production and exocytosis. Several protein markers, including tetraspanins (CD9, CD63, CD81, and CD82), ALIX, TSG101, flotillin, heat shock proteins (HSP70, HSC70, HSP90), and T-complex protein 1 subunit beta (CCT2), are suggested as markers to differentiate sEVs (exosomes) from other EVs [211,212], even though they are recognizable by electron microscopy thanks to their typical biconcave or cup-like shape.

3.3. Function, Isolation, and Storage

Initially, sEVs (exosomes) were considered to be cellular waste released after cell damage or as unnecessary products of cell homeostasis, with no significant function and impact on neighboring cells [213]. The important role of sEVs (exosomes) as actual mediators of physiological pathways was revealed 10 years after their discovery by Raposo et al. [199] and, later, a plethora of other studies. sEVs (exosomes) are ubiquitous in healthy or pathological conditions and found to be secreted in biofluids, such as urine [214], blood plasma and serum [215], breast milk [216], colostrum [217], amniotic fluid [218], tears [219], vitreous humor [220], aqueous humor [221], synovial fluid [222], saliva [223], and tumor ascites [224]. sEVs (exosomes) represent a novel route of cell-to-cell communication [225]. When reaching the target cells, sEVs (exosomes) release their complex cargo, represented by proteins, metabolites, lipids, DNA, RNA and small non-coding RNAs (including miRNAs) (Figure 2), which may eventually reprogram the recipient cells [71,199]. Thus, sEVs (exosomes) and their biologically active cargo may be important in a variety of physiological or pathological processes, including immune response [99,226,227], inflammation [228–230], signal transduction [231–233], angiogenesis [234–236], antigen presentation [237–239], neurodegenerative diseases [240–242], cardiovascular diseases [243–245], renal diseases [246–248], viral infection [249–251], pregnancy [252–254], cancer progression [255–257], and cell death [98,258,259].




Figure 2. Exosomal cargo. During the process of budding of the inner membrane of the early endosome, some proteins are incorporated into the invaginating membrane, and the cytosolic components are enclosed inside [198]. sEVs (exosomes) contain selective repertoires of proteins, DNA, messenger RNA (mRNA), non-coding RNAs (miRNA), lipids, and metabolites that moderate signaling pathways in the recipient cells [71,199]. Tetraspanins (CD9, CD63, CD81, and CD82) or chaperones (HSP70, HSC70, and HSP90) represent exosomal markers [211,212]. Biologically active cargo of sEVs (exosomes) participates in several physiological or pathological processes, including cancer. An original figure. The figure was created using Inkscape v1.1.2 software.

To allow the application of sEVs (exosomes) as biomarkers, effective isolation methods and optimal storage conditions are crucial. The most commonly used method is ultracentrifugation, followed by ultrafiltration, differential centrifugation, microfluid-based techniques, immunoaffinity chromatography, the polyethylene glycol-based precipitation method, and size-exclusion chromatography [260]. Each technique has its pros and cons and differs in the processing of the sample and the purity and quality of the exosomes obtained (reviewed in [261,262]). Commercial kits are also available on the market, like exoEasy Maxi kit (Qiagen, Hilden, Germany), Total Exosome Isolation Kit (Invitrogen™), ExoQuick® (System Biosciences, Palo Alto, CA, USA), MagCapture™ Exosome Isolation Kit PS (Wako, Richmond, VA, USA), Exosome Isolation Kit Pan (Miltenyi Biotec Inc., Cologne, Germany), Intact Exosome Purification (Norgen Biotek Corp., Thorold, ON, Canada) or Minute™ Hi-Efficiency Exosome Precipitation Reagent (Invent, Plymouth, MN, USA). Commercial kits are time-saving and less laborious. At the same time, kits are expensive, and several studies have demonstrated that different kits may introduce variations in the concentration, purity, and size of sEVs (exosomes) [263–265]. Thus, when evaluating results, it is necessary to take into account the advantages and disadvantages of individual isolation methods of EVs.

The great advantage of sEVs (exosomes) is the possibility of their long-term storage at lower temperatures before analysis, with no or minor impact on exosome yield or bioactivity [171,266]. However, storage temperature depends on the sEVs (exosomes) source. For example, urine exosomes are sensitive to the storage temperature [267]. Zhou et al. showed that storage of urine samples at $-20\text{ }^{\circ}\text{C}$ led to a significant loss of exosomes compared to freshly collected urine. Preservation at $-80\text{ }^{\circ}\text{C}$ combined with extensive vortexing after thawing maximized the efficiency of exosome recovery [267]. On the other hand,

multiple studies have shown that blood components, such as plasma or serum, can be stored long-term (for several years) either at 4 °C, −20 °C or −80 °C, and even at room temperature for short time (1–2 days), with no significant exosome or exosome-associated RNA and proteins degradation [268–272]. However, the study of Dutta et al. showed a decrease in central nervous system-derived α -synuclein stability upon storing serum or plasma-originated exosomes after 5 years at −80 °C [273].

To summarize, the ability of exosomes to transfer regulatory messages to other cells and their availability and stability make them a valuable source of biomarkers.

3.4. Exosome-Derived miRNAs as Biomarkers

Nowadays, sEVs (exosomes) are of interest in biomarker research. Naturally, this raises the question of why exactly sEVs (exosomes)? Exosome cargo (represented by nucleic acids, proteins, peptides, lipids, and metabolites; Figure 2) is specific and may vastly differ among various cell types, even from the same primary cell [274], depending on their function and current state (e.g., normal, transformed, differentiated, stimulated, and stressed). Thus, cell- or condition-specific sEV (exosome) content is something like a fingerprint of the donor cell reflecting the cellular processes and, therefore, may serve as biomarkers for various diseases [213]. Principally, the demonstration of miRNAs association with EVs by Valadi et al. in 2007 [71] open the way for a multitude of studies dealing with EV-associated miRNAs. Exosome-derived miRNAs have attracted considerable attention as non-invasive biomarkers of various diseases with diagnostic and prognostic potential [183,275,276]. To describe selectively packaged, secreted, and transferred miRNAs between cells in sEVs (exosomes) and distinguish them from circulating miRNAs, Bhome et al. introduced the term “exomiRs” [277]. These exomiRs offer some beneficial factors over circulating miRNAs that increased their importance as biomarkers. Except for the above-mentioned fact that the miRNA profile presents a signature of the parental cell, sEVs (exosomes)-packaged miRNAs are highly protected from degradation, even in non-optimal storage conditions and in the presence of RNases, hence conditions that normally degrade free miRNAs [277–279]. Indeed, sEVs (exosomes) are considered to be a stable source of miRNAs, and exosomal miRNAs in biofluids are more stable in comparison to circulating miRNAs [280]. ExomiRs have been shown to maintain stability either for short-term storage (2 weeks) at 4 °C or long-term storage (5 years) at −20 °C, as well as resistance to freeze–thaw cycles [171]. Due to their ease of access and stability, exomiRs represent a minimally invasive tool for the diagnosis and prognosis of cancer. The fact that exomiRs are also secreted by other cell types and not only cancer cells could mask cancer-specific biomarkers [278]. Profiling multiple exomiRs markers and isolating exosomes using tumor-specific protein markers could improve exosomal miRNAs sensitivity and specificity [278].

Today, research generally monitors and measures miRNAs, as well as exomiRs, using microarrays and real-time PCR (RT-PCR) [275]. Microarrays can detect many aberrant miRNAs with the entire genome expression profiling of miRNAs in the sample, but without determination of absolute quantification [275,281]. Being more sensitive and specific, RT-PCR allows the detection of low-level miRNAs with the determination of absolute quantification [275,281]. However, it cannot be used to identify novel miRNAs [281]. Novel miRNAs and miRNAs distinguished only by one nucleotide can be detected by the accurate and sensitive method of RNA sequencing because no primers or probes are needed [275,281]. RNA sequencing was already applied in the detection of exosomal miRNAs [282–284].

3.5. ExomiRs in Canine Mammary Cancer

Cancer cell-derived sEVs (exosomes) are not only inert cellular by-products but are, indeed, functionally and biologically important in neoplastic transformation [285] and/or tumor progression (reviewed in [205,286]). Cancer cells have been found to secrete more sEVs (exosomes) than non-malignant cells [287–291]. For instance, the concentration of exosomes quantified by Exotest (author-designed ELISA) using CD63 and caveolin-1 as

detection antigens was significantly ($p < 0.001$) higher in melanoma patients with respect to healthy [289]. More production of sEVs (exosomes) (quantified using nanoparticle tracking analysis and expression of the suggested markers of sEVs (exosomes)—Alix and TSG101) by B42 clone 16 breast cancer cell line [$(53.2 \pm 1.6) \times 10^8$ exosomes per 10^6 cells] compared to normal mammary epithelial cells HMEC B42 [$(4.5 \pm 2.3) \times 10^8$ exosomes per 10^6 cells] was demonstrated by Riches et al. [288]. A two-fold increase in the number of sEVs (exosomes) (with sizes in the range 85–150 nm confirmed using nanoparticle tracking analysis) from plasma (13.3×10^{11} particles/mL) and serum (9.9×10^{11} particles/mL) of human prostate cancer patients in comparison to the healthy control (4.15×10^{11} particles/mL) indicate that tumor cells produce more sEVs (exosomes) than the normal cells [287]. The relative concentration of circulating sEVs (exosomes) with confirmed a lipid bilayer and CD9 positivity was significantly higher ($p < 0.05$) also in the sera of patients with pancreatic ductal adenocarcinoma compared to healthy donors [290]. Additionally, significantly ($p < 0.001$) greater levels of sEVs (exosomes) with vesicular structures and size ≤ 100 nm confirmed by electron microscopy associated with three stages (I, II, and III) of ovarian cancer than in benign disease or controls were observed [291]. These findings may indicate the potential role of tumor-derived sEVs (exosomes) in malignancy. sEVs (exosomes) released from the cancer cells have a strong capacity to affect cancer progression in several ways, including promotion of cancer cell migration [292], invasion [293], angiogenesis [234], vascular permeability [294], drug resistance [295], or intracellular communication during tumor development by autocrine and paracrine secretion of exosomal cargo (represented by proteins, metabolites, DNAs, RNAs, and miRNAs; Figure 2) [296]. Since miRNAs are considered as the major functional molecules of sEVs (exosomes) in intercellular communication, recruitment, and reprogramming important components of the tumor microenvironment [71], they are intensively studied among the exosomal RNA contents. Several studies indicated that sEVs (exosomes) contain high levels of miRNAs, which have been shown to contribute to metastasis [297], immunomodulation [298], chemoresistance [299], angiogenesis and vascular permeability [294] in multiple tumor types. Moreover, exosomal miRNAs were suggested as potential biomarkers for diagnosis and prognosis in various types of cancer, such as miR-320d for metastatic colorectal cancer [300], miR-10-5p for early-stage hepatocellular carcinoma [301], miR-106b for lung cancer [302] or miR-34a for ovarian cancer [303]. As sEVs' (exosomes) isolation methods vary with respect to purity, a mixture of sEVs (exosomes) and other vesicles may be found in the isolated fraction. The identity of sEVs (exosomes) mentioned in this review was confirmed either by transmission electron microscopy [294,297–303] or by the presence of exosome-specific markers, such as CD9, CD91, CD63, HSP70 or TSG101 [294,298,300,302,303], and size distribution (30–150 nm) was validated by nanoparticle tracking analysis [294,297,298,300].

sEVs (exosomes) research in veterinary medicine is still at an early stage, which is underlined by the first articles from 2017 [304–307]. The majority of recently published studies are mainly focused on canine and feline cancers [256,257,307–314]. Regarding exomiRs in canine cancer, our literature review revealed only a few studies analyzing miRNAs in canine oral melanoma [314], multicentric lymphomas [312], and lymphoid tumor cell lines [310].

To the best of our knowledge, in 2018, Fish et al. published the first and so far only study reporting the shedding of exosome-derived miRNA by canine mammary cells in vitro [309]. In particular, cell-free conditioned media containing exosome-like vesicles from three normal canine mammary epithelial cell cultures from canine patients without mammary pathology and five canine mammary tumor cell lines with histopathology-confirmed mammary carcinoma (CMT12, CMT27, CMT28, CMT47, CMT119) were used to yield a number of significantly upregulated and downregulated exomiRs that may represent putative biomarkers of mammary neoplasia. This complex study detected 338 unique exomiRs with 145 differentially expressed exomiRs (118 upregulated and 27 downregulated) having $>\pm 1.5$ -fold difference between tumor and normal samples.

Two proposed circulating low-invasive biomarkers in canine neoplastic diseases, including mammary carcinoma [315], miR-126, and miR-214, were also monitored in mammary tumors-exosomes. Generally, both miRNAs demonstrated a broad influence on cancer pathogenesis through the regulation of angiogenesis, proliferation, migration, and cancer cell death [316,317]. Therefore, alteration in their expression has a critical impact on tumor progression. In this study, miR-126 was found to be upregulated (2.25-fold). Thus, miR-126 may represent a prospective exosomal miRNA-based biomarker in canine mammary tumors. However, the expression of miR-214 was strongly downregulated (−9.13-fold) in the exosomal RNA of canine mammary tumors. As explained by the authors, high levels of miR-214 monitored in canine neoplastic diseases, including mammary cancer, can be either a result of secretion of other than canine mammary tumors cells (i.e., cells of the immune system, stroma or other organs) or a mismatch between tumor cell, exosomal and circulating miRNA profiles [309].

The findings of this study correlate with previously published studies on miRNAs in CMC discussed above. Several miRNAs, including miR-18a, miR-19a, miR-29b/c, miR-181a/b, miR-215, miR-345, miR-371, and miR-1841, were found to be upregulated in both canine mammary tumor cells and their exosomes [110,116,117,121]. However, some discrepancies in exomiRs expression levels compared to miRNAs profiles of tumor cells in other studies were observed, such as miR-19a, miR-29b/c, miR-31, miR-34c, miR-181a/b, miR-155, and miR-495 [113,114,117]. As discussed by the authors, this inconsistency may be a result of the active selection or enrichment process of particular miRNAs within exosomes or as a consequence of dramatic changes in tumor cell phenotype and gene expression in metastatic lesions [309].

In the same study, gene ontology enrichment analysis showed the cellular role of exomiRs in the regulation of enriched biological processes, such as positive regulation of cell proliferation, positive regulation of the apoptotic process, cell migration, response to hypoxia, regulation of gene expression, negative regulation of cell migration, or chromatin remodeling (histone ubiquitination or trimethylation) [309]. Target gene representation analysis associated with enriched gene ontology terms in order to select suitable candidates for clinical biomarker applications identified three miRNAs: miR-18a, miR-19a, and miR-181a [309]. These miRNAs were also the most significantly upregulated among all exomiRs (10.34-fold, 3.84-fold, and 7.70-fold, respectively) [309]. Moreover, miR-18a, miR-19a, and miR-181a were predicted *in silico* to target the estrogen receptor (ESR1 α), the expression of which is known to be lost in human and canine neoplasms along with increasing grade and stage (miR-18a: miRDB target score = 99; miR-19a: miRDB target score = 71, and miR-181a: miRDB target score = 79) [309]. Based on these findings, the authors assume that miR-18a, miR-19a, and miR-181a represent non-invasive markers of hormone status and phenotype in CMC [309].

In contrast to CMC, there are several studies suggesting exosomal miRNAs as biomarkers for HBC. In these studies, several exomiRs were proposed as diagnostic biomarkers (miR-10b, miR-21, miR-101-3p, miR-105-5p, miR-134, miR-200c, miR-372) [219,318–321], prognostic biomarkers (miR-17-5p, miR-18a-5p, miR-20b-5p, miR-21, miR-29b-3p, miR-93-5p, miR-105, miR-124-3p, miR-130a-3p, miR-195-5p, miR-200c-3p, miR-338-3p, miR-340-5p, miR-486-5p, miR-1246) [219,319,322,323] of breast cancer, or indicators of a triple-negative phenotype (miR-373) [318].

Some of these HBC exomiRs were also identified in the canine study of Fish et al. [309]. In particular, cfa-miR-18a (hsa-mir-18a-5p), cfa-miR-20b (hsa-miR-20b-5p), cfa-miR-21 (hsa-miR-21), miR-29b (hsa-miR-29b-3p), miR-93 (hsa-miR-93-5p), cfa-miR-101 (hsa-miR-101-3p), cfa-miR-105a (hsa-miR-105-5p), cfa-miR-130a (hsa-miR-130a-3p), cfa-miR-200c (hsa-miR-200c-3p), cfa-miR-340 (hsa-340-5p), and cfa-miR-486 (hsa-miR-486-5p). These data show that CMC and HBC cells exclude sEVs (exosomes) enriched in differentially expressed miRNAs. The identification of exomiRs in exosomes excluded by cancer cells indicates the possibility of also detecting them in biofluids, such as blood or urine. This allows their use

as non- or minimally invasive biomarkers. Furthermore, the observed similarity between CMC and HBC exomiRs profiles may have significance for translational research [309].

4. Conclusions

The non-exosomal and exosome-derived miRNAs identified in CMC as promising biomarkers reviewed in this study reveal heterogeneity in relation to expression level, potential use, and sampling (Table 2).

Table 2. Overview of non-exosomal and exosome-derived microRNAs (miRNAs) altered in canine mammary cancer with biomarker potential.

Non-Exosomal miRNAs				
miRNA	Expression Level	Potential Use	Sample	Reference
miR-21	up	diagnostic	tumor	[110,113,115]
	up	prognostic	blood serum	[119]
	up	metastatic	tumor	[114]
	up	diagnostic	blood serum	[120]
miR-29b	up	diagnostic	tumor	[110]
	up	diagnostic	blood serum	[121]
	up	diagnostic	cell line	[116]
	down	diagnostic	tumor	[113]
	down	prognostic	blood serum	[119]
	down	metastatic	tumor	[114]
miR-141	up	diagnostic and prognostic	cell line	[117]
miR-429	up	diagnostic	cell line	[117]
miR-200c	up	diagnostic	cell line	[117]
miR-497	down	therapeutic	cell line	[118]
miR-10b	down	metastatic	tumor	[113]
miR-101	down	metastatic	tumor	[113]
miR-125a/b	down	metastatic	tumor	[113,114]
miR-136	down	metastatic	tumor	[113]
miR-143	down	metastatic	tumor	[113]
	up	diagnostic	tumor	[114]
	up	diagnostic	cell line	[116]
miR-145 let-7f	down	metastatic	tumor	[113]
	down	metastatic	tumor	[113]
miR-203	down	diagnostic	tumor	[113]
	up	metastatic	tumor	[114]
miR-210	up	diagnostic	tumor	[113,114]
miR-138a	down	diagnostic	cell line	[116]
miR-8832	down	diagnostic	tumor	[111]
miR-96	up	diagnostic	tumor	[111]
miR-149	down	diagnostic	tumor	[111]
miR-18a	up	prognostic	blood serum	[121]
miR-19b	up	diagnostic	blood serum	[121]
Exosome-derived miRNAs				
miR-126	up	diagnostic	conditioned medium	[309]
miR-214	down	diagnostic	conditioned medium	[309]
miR-18a	up	diagnostic	conditioned medium	[309]
miR-19a	up	diagnostic	conditioned medium	[309]
miR-181a	up	diagnostic	conditioned medium	[309]

Please note that miRNAs are listed based on their occurrence in the article.

However, CMC mimics human breast tumors in many aspects (histopathology, clinical outcome or molecular markers). The similarities in terms of function and dynamics of miRNAs in mammary/breast cancer point to the role of these small non-coding RNAs in

cancer mechanisms of both canine and human origin. MiRNAs are post-transcriptional regulators of gene expression with an impact on practically all cellular physiological and pathological processes. Since miRNAs are involved in cancer-related processes (such as carcinogenesis, cell proliferation, invasion, metastasis, apoptosis or chemoresistance), their diagnostic, prognostic, and therapeutic significance has been proposed. Over the past few years, several studies regarding miRNA-based biomarkers of mammary cancer have been carried out in canine patients. Most of these studies were focused on miRNAs derived from tumors or cancer cell lines. However, a traditional solid biopsy is gradually receding and more often is being replaced by liquid biopsy, wherein biofluid-extracted biomarkers provide a platform for non-invasive or minimally invasive diagnosis and prognosis. sEVs (exosomes) are present in many biological fluids and can be used similarly for minimally invasive liquid biopsies in veterinary medicine. Furthermore, their cargo plays an important role in various physiological and pathological processes. In particular, exosome-derived miRNAs have been shown to have a complex role in tumorigenesis and tumor progression. However, utilizing sEVs (exosomes) and their exomiRs cargo as a diagnostic tool for CMC is still in its infancy and requires further investigation. Moreover, most of the presented studies were conducted on small groups of patients. Although all of the above-mentioned miRNAs-based biomarkers seem to have diagnostic or prognostic potential in CMC, more detailed studies should be carried out in the near future.

Author Contributions: Conceptualization, P.P. and D.C.; writing—the literature review and original draft preparation, P.P.; writing—review and editing, D.C., N.H., M.M. and F.H.; figure preparation, N.H.; supervision, D.C. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by APVV-19-0193 and VEGA 1/0376/20.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: No new data were created or analyzed in this study. Data sharing is not applicable to this article.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

<i>ADCY6</i>	gene encoding adenylyl cyclase type 6
<i>Ago2</i>	Argonaute 2
<i>ALIX</i>	apoptosis-linked gene 2-interacting protein X
<i>BMI</i>	body mass index
<i>BRCA1</i>	breast cancer gene 1
<i>BRCA2</i>	breast cancer gene 2
<i>BRPF3</i>	gene encoding bromodomain and PHD finger containing 3
<i>CCT2</i>	T-complex protein 1 subunit beta
<i>CDKN2A</i>	gene encoding cyclin-dependent kinase inhibitor 2A
<i>CEA</i>	carcinoembryonic antigen
<i>cfa</i>	<i>Canis lupus familiaris</i>
<i>c-KIT</i>	gene encoding tyrosine-protein kinase KIT
<i>CMC</i>	canine mammary cancer
<i>DGCR8</i>	DiGeorge syndrome critical region gene 8
<i>dPCR</i>	digital droplet PCR
<i>EGF</i>	epidermal growth factor
<i>EGFR</i>	epidermal growth factor receptor
<i>EMT</i>	epithelial-mesenchymal transition

ERRFI1	ERBB receptor feedback inhibitor 1
ER α	estrogen receptor alfa
ERCC1	DNA excision repair protein
ESCRT	endosomal sorting complexes required for transport
EVs	extracellular vesicles
GNAO1	gene encoding guanine nucleotide-binding protein-alpha O1
HBC	human breast cancer
HER2	human epidermal growth factor receptor 2
HER3	human epidermal growth factor receptor 3
HIF1 α	hypoxia-inducible factor 1-alpha
hsa	<i>Homo sapiens</i>
HSP	heat shock protein
ICAM-1	intercellular adhesion molecule 1
IGF-1	insulin-like growth factor-1
ING3	human epidermal growth factor receptor 3
INK4	inhibitor of CDK4
IRAK2	gene encoding interleukin-1 receptor-associated kinase-like 2
ISEV	The International Society for Extracellular Vesicles
JNK	c-Jun N-terminal Kinase
K-RAS	gene for Kirsten rat sarcoma virus
LRIG1	gene encoding leucine-rich repeats and immunoglobulin-like domains 1
m/IEVs	medium/large extracellular vesicles
MAPK	gene encoding mitogen-activated protein kinase
miRNA	microRNA
MMP2	matrix metalloproteinase-2
mRNA	messenger RNA
MVB	multivesicular bodies
MYLIP	myosin regulatory light chain interacting protein
NF-kB	nuclear factor kappa-light-chain-enhancer of activated B cells
NGS	Nottingham histological grade
PACT	protein kinase RNA activator
PCNA	proliferating cell nuclear antigen
PCP	planar cell polarity
PCR	polymerase chain reaction
PECAM-1	platelet endothelial cell adhesion molecule-1
PI3K/AKT	phosphatidylinositol-4,5-bisphosphate 3-kinase/protein kinase B
Pre-miRNA	precursor miRNA
Pri-miRNA	primary miRNA
PTEN	gene encoding phosphatase and tensin homolog
RISC	RNA-induced silencing complex
RNF2	gene encoding E3 ubiquitin-protein ligase RING2
ROC-AUC	receiver operator characteristic-area under the curve
RT-PCR	real time-PCR
sEVs	small extracellular vesicles
SOX2	(sex determining region Y)-box 2
TNRC6A	trinucleotide repeat-containing gene 6A protein
TP53	gene encoding tumor protein 53
TRBP	transactivation response RNA binding protein
TSG101	tumor susceptibility gene 101 protein
UGT1A1	gene encoding UDP-glucuronosyltransferase 1-1 enzymeuntranslated regions
UTR	
VEGF	vascular endothelial growth factor
VEGF-A	vascular endothelial growth factor A
VPS4	vacuolar protein sorting-associated protein
VTA1	vesicle trafficking 1
WHO	World Health Organisation
Wnt	Wingless and Int-1
YAP1	yes-associated protein 1

References

1. Sultan, F.; Ganaie, B.A. Comparative oncology: Integrating human and veterinary medicine. *Open Vet. J.* **2018**, *8*, 25. [[CrossRef](#)] [[PubMed](#)]
2. Stephens, T. The Use of Chemotherapy to Prolong the Life of Dogs Suffering from Cancer: The Ethical Dilemma. *Animal* **2019**, *9*, 441. [[CrossRef](#)] [[PubMed](#)]
3. Rutteman, G.R. Hormones and mammary tumour disease in the female dog: An update. *In Vivo Athens Greece* **1990**, *4*, 33–40.
4. Sorenmo, K. Canine mammary gland tumors. *Vet. Clin. N. Am. Small Anim. Pract.* **2003**, *33*, 573–596. [[CrossRef](#)]
5. Benavente, M.A.; Bianchi, C.P.; Aba, M.A. Canine Mammary Tumors: Risk Factors, Prognosis and Treatments. *J. Vet. Adv.* **2016**. [[CrossRef](#)]
6. Priester, W.A. Occurrence of mammary neoplasms in bitches in relation to breed, age, tumour type, and geographical region from which reported. *J. Small Anim. Pract.* **1979**, *20*, 1–11. [[CrossRef](#)]
7. Baioni, E.; Scanziani, E.; Vincenti, M.C.; Leschiera, M.; Bozzetta, E.; Pezzolato, M.; Desiato, R.; Bertolini, S.; Maurella, C.; Ru, G. Estimating canine cancer incidence: Findings from a population-based tumour registry in northwestern Italy. *BMC Vet. Res.* **2017**, *13*, 203. [[CrossRef](#)]
8. Egenvall, A.; Bonnett, B.N.; Ohagen, P.; Olson, P.; Hedhammar, A.; von Euler, H. Incidence of and survival after mammary tumors in a population of over 80,000 insured female dogs in Sweden from 1995 to 2002. *Prev. Vet. Med.* **2005**, *69*, 109–127. [[CrossRef](#)]
9. Beauvais, W.; Cardwell, J.M.; Brodbelt, D.C. The effect of neutering on the risk of mammary tumours in dogs—A systematic review. *J. Small Anim. Pract.* **2012**, *53*, 314–322. [[CrossRef](#)]
10. Schneider, R.; Dorn, C.R.; Taylor, D.O.N. Factors Influencing Canine Mammary Cancer Development and Postsurgical Survival. *JNCI J. Natl. Cancer Inst.* **1969**, *43*, 1249–1261. [[CrossRef](#)]
11. Dorn, C.R.; Taylor, D.O.N.; Schneider, R.; Hibbard, H.H.; Klauber, M.R. Survey of Animal Neoplasms in Alameda and Contra Costa Counties, California. II. Cancer Morbidity in Dogs and Cats From Alameda County. *JNCI J. Natl. Cancer Inst.* **1968**, *40*, 307–318. [[CrossRef](#)] [[PubMed](#)]
12. Sonnenschein, E.G.; Glickman, L.T.; Goldschmidt, M.H.; McKee, L.J. Body Conformation, Diet, and Risk of Breast Cancer in Pet Dogs: A Case-Control Study. *Am. J. Epidemiol.* **1991**, *133*, 694–703. [[CrossRef](#)] [[PubMed](#)]
13. Alenza, D.P.; Rutteman, G.R.; Peña, L.; Beynen, A.C.; Cuesta, P. Relation between Habitual Diet and Canine Mammary Tumors in a Case-Control Study. *J. Vet. Intern. Med.* **1998**, *12*, 132–139. [[CrossRef](#)] [[PubMed](#)]
14. Petrov, E.A.; Ilievska, K.; Trojancanec, P.; Celeska, I.; Nikolovski, G.; Gjurovski, I.; Dovenski, T. Canine Mammary Tumours-Clinical Survey. *Maced. Vet. Rev.* **2014**, *37*, 129–134. [[CrossRef](#)]
15. Sleeckx, N.; de Rooster, H.; Veldhuis Kroeze, E.; Van Ginneken, C.; Van Brantegem, L. Canine Mammary Tumours, an Overview. *Reprod. Domest. Anim.* **2011**, *46*, 1112–1131. [[CrossRef](#)]
16. Vail, D.M.; MacEwen, E.G. Spontaneously occurring tumors of companion animals as models for human cancer. *Cancer Invest.* **2000**, *18*, 781–792. [[CrossRef](#)]
17. Canadas, A.; França, M.; Pereira, C.; Vilaça, R.; Vilhena, H.; Tinoco, F.; Silva, M.J.; Ribeiro, J.; Medeiros, R.; Oliveira, P.; et al. Canine Mammary Tumors: Comparison of Classification and Grading Methods in a Survival Study. *Vet. Pathol.* **2019**, *56*, 208–219. [[CrossRef](#)]
18. Wim, M.; Armed Forces Institute of Pathology (USA); American Registry of Pathology; WHO Collaborating Center for Worldwide Reference on Comparative Oncology. *Histological Classification of Mammary Tumors of the Dog and the Cat*; Armed Forces Institute of Pathology in Cooperation with the American Registry of Pathology: Washington, DC, USA; The World Health Organization Collaborating Center for Worldwide Reference on Comparative Oncology: Washington, DC, USA, 1999, ISBN 978-1-881041-66-5.
19. Goldschmidt, M.; Peña, L.; Rasotto, R.; Zappulli, V. Classification and Grading of Canine Mammary Tumors. *Vet. Pathol.* **2011**, *48*, 117–131. [[CrossRef](#)]
20. Salas, Y.; Márquez, A.; Diaz, D.; Romero, L. Epidemiological Study of Mammary Tumors in Female Dogs Diagnosed during the Period 2002–2012: A Growing Animal Health Problem. *PLoS ONE* **2015**, *10*, e0127381. [[CrossRef](#)]
21. Simon, D.; Schoenrock, D.; Nolte, I.; Baumgärtner, W.; Barron, R.; Mischke, R. Cytologic examination of fine-needle aspirates from mammary gland tumors in the dog: Diagnostic accuracy with comparison to histopathology and association with postoperative outcome. *Vet. Clin. Pathol.* **2009**, *38*, 521–528. [[CrossRef](#)]
22. Cassali, G.D.; Gobbi, H.; Malm, C.; Schmitt, F.C. Evaluation of accuracy of fine needle aspiration cytology for diagnosis of canine mammary tumours: Comparative features with human tumours. *Cytopathol. Off. J. Br. Soc. Clin. Cytol.* **2007**, *18*, 191–196. [[CrossRef](#)] [[PubMed](#)]
23. Elston, C.W.; Ellis, I.O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. *Histopathology* **1991**, *19*, 403–410. [[CrossRef](#)] [[PubMed](#)]
24. Frese, K. Comparative pathology of breast tumors in domestic animals. *Verh. Dtsch. Ges. Pathol.* **1985**, *69*, 152–170. [[PubMed](#)]
25. Owen, L.N. A comparative study of canine and human breast cancer. *Invest. Cell Pathol.* **1979**, *2*, 257–275. [[PubMed](#)]
26. Queiroga, F.L.; Raposo, T.; Carvalho, M.I.; Prada, J.; Pires, I. Canine Mammary Tumours as a Model to Study Human Breast Cancer: Most Recent Findings. *In Vivo* **2011**, *25*, 455–465.
27. Gilbertson, S.R.; Kurzman, I.D.; Zachrau, R.E.; Hurvitz, A.I.; Black, M.M. Canine Mammary Epithelial Neoplasms: Biologic Implications of Morphologic Characteristics Assessed in 232 Dogs. *Vet. Pathol.* **1983**, *20*, 127–142. [[CrossRef](#)]

28. Rosol, T.J.; Tannehill-Gregg, S.H.; LeRoy, B.E.; Mandl, S.; Contag, C.H. Animal models of bone metastasis. *Cancer* **2003**, *97*, 748–757. [[CrossRef](#)]
29. O’Shaughnessy, J. Extending Survival with Chemotherapy in Metastatic Breast Cancer. *Oncologist* **2005**, *10*, 20–29. [[CrossRef](#)]
30. Ostrander, E.A. Both Ends of the Leash—The Human Links to Good Dogs with Bad Genes. *N. Engl. J. Med.* **2012**, *367*, 636–646. [[CrossRef](#)]
31. Duffy, M.J.; O’Donovan, N.; Crown, J. Use of molecular markers for predicting therapy response in cancer patients. *Cancer Treat. Rev.* **2011**, *37*, 151–159. [[CrossRef](#)]
32. Mehta, S.; Shelling, A.; Muthukaruppan, A.; Lasham, A.; Blenkiron, C.; Laking, G.; Print, C. Predictive and prognostic molecular markers for cancer medicine. *Ther. Adv. Med. Oncol.* **2010**, *2*, 125–148. [[CrossRef](#)] [[PubMed](#)]
33. Kaszak, I.; Ruszczak, A.; Kanafa, S.; Kacprzak, K.; Król, M.; Jurka, P. Current biomarkers of canine mammary tumors. *Acta Vet. Scand.* **2018**, *60*, 66. [[CrossRef](#)] [[PubMed](#)]
34. Mahdavi, M.; Nassiri, M.; Kooshyar, M.M.; Vakili-Azghandi, M.; Avan, A.; Sandry, R.; Pillai, S.; Lam, A.K.-Y.; Gopalan, V. Hereditary breast cancer; Genetic penetrance and current status with BRCA. *J. Cell. Physiol.* **2019**, *234*, 5741–5750. [[CrossRef](#)] [[PubMed](#)]
35. Rivera, P.; Melin, M.; Biagi, T.; Fall, T.; Häggström, J.; Lindblad-Toh, K.; von Euler, H. Mammary Tumor Development in Dogs Is Associated with BRCA1 and BRCA2. *Cancer Res.* **2009**, *69*, 8770–8774. [[CrossRef](#)] [[PubMed](#)]
36. Calle, E.E.; Kaaks, R. Overweight, obesity and cancer: Epidemiological evidence and proposed mechanisms. *Nat. Rev. Cancer* **2004**, *4*, 579–591. [[CrossRef](#)] [[PubMed](#)]
37. Abdelmegeed, S.M.; Mohammed, S. Canine mammary tumors as a model for human disease (Review). *Oncol. Lett.* **2018**, *15*, 8195–8205. [[CrossRef](#)]
38. Khanna, C.; Lindblad-Toh, K.; Vail, D.; London, C.; Bergman, P.; Barber, L.; Breen, M.; Kitchell, B.; McNeil, E.; Modiano, J.F.; et al. The dog as a cancer model. *Nat. Biotechnol.* **2006**, *24*, 1065–1066. [[CrossRef](#)]
39. Weigelt, B.; Horlings, H.M.; Kreike, B.; Hayes, M.M.; Hauptmann, M.; Wessels, L.F.A.; de Jong, D.; Van de Vijver, M.J.; Van’t Veer, L.J.; Peterse, J.L. Refinement of breast cancer classification by molecular characterization of histological special types. *J. Pathol.* **2008**, *216*, 141–150. [[CrossRef](#)]
40. Zambrano-Estrada, X.; Landaverde-Quiroz, B.; Dueñas-Bocanegra, A.A.; De Paz-Campos, M.A.; Hernández-Alberto, G.; Solorio-Perusquia, B.; Trejo-Mandujano, M.; Pérez-Guerrero, L.; Delgado-González, E.; Anguiano, B.; et al. Molecular iodine/doxorubicin neoadjuvant treatment impair invasive capacity and attenuate side effect in canine mammary cancer. *BMC Vet. Res.* **2018**, *14*, 87. [[CrossRef](#)]
41. Conforti, A.; Impellizzeri, J.; Aurisicchio, L. Immunotherapy Applications (Telomerase and HER2) with Gene Electrotransfer. In *Electroporation in Veterinary Oncology Practice: Electrochemotherapy and Gene Electrotransfer for Immunotherapy*; Impellizzeri, J.A., Ed.; Springer International Publishing: Cham, Switzerland, 2021; pp. 235–252, ISBN 978-3-030-80668-2.
42. Cassali, G.D.; Lavalle, G.E.; de Nardi, A.B.; Ferreira, E.; Bertagnolli, A.C.; Estrela-Lima, A.; Alessi, A.C.; Daleck, C.R.; Salgado, B.S.; Fernandes, C.G.; et al. Consensus for the diagnosis, prognosis and treatment of canine mammary tumors. *Braz. J. Vet. Pathol.* **2011**, *4*, 153–180.
43. Levi, M.; Brunetti, B.; Sarli, G.; Benazzi, C. Immunohistochemical Expression of P-glycoprotein and Breast Cancer Resistance Protein in Canine Mammary Hyperplasia, Neoplasia and Supporting Stroma. *J. Comp. Pathol.* **2016**, *155*, 277–285. [[CrossRef](#)] [[PubMed](#)]
44. Simon, D.; Schoenrock, D.; Baumgärtner, W.; Nolte, I. Postoperative Adjuvant Treatment of Invasive Malignant Mammary Gland Tumors in Dogs with Doxorubicin and Docetaxel. *J. Vet. Intern. Med.* **2006**, *20*, 1184–1190. [[CrossRef](#)] [[PubMed](#)]
45. Henry, N.L.; Hayes, D.F. Cancer biomarkers. *Mol. Oncol.* **2012**, *6*, 140–146. [[CrossRef](#)] [[PubMed](#)]
46. Chatterjee, S.K.; Zetter, B.R. Cancer biomarkers: Knowing the present and predicting the future. *Future Oncol. Lond. Engl.* **2005**, *1*, 37–50. [[CrossRef](#)] [[PubMed](#)]
47. Califf, R.M. Biomarker definitions and their applications. *Exp. Biol. Med.* **2018**, *243*, 213–221. [[CrossRef](#)]
48. Wagner, P.D.; Verma, M.; Srivastava, S. Challenges for biomarkers in cancer detection. *Ann. N. Y. Acad. Sci.* **2004**, *1022*, 9–16. [[CrossRef](#)] [[PubMed](#)]
49. Zhang, X.; Sun, X.-F.; Shen, B.; Zhang, H. Potential Applications of DNA, RNA and Protein Biomarkers in Diagnosis, Therapy and Prognosis for Colorectal Cancer: A Study from Databases to AI-Assisted Verification. *Cancers* **2019**, *11*, 172. [[CrossRef](#)]
50. Mahendru, S.; Roy, K.; Kukreti, S. Peptide Biomarkers: Exploring the Diagnostic Aspect. *Curr. Protein Pept. Sci.* **2017**, *18*, 914–919. [[CrossRef](#)]
51. Boschetti, E.; D’Amato, A.; Candiano, G.; Righetti, P.G. Protein biomarkers for early detection of diseases: The decisive contribution of combinatorial peptide ligand libraries. *J. Proteom.* **2018**, *188*, 1–14. [[CrossRef](#)]
52. Liu, D.; Meister, M.; Zhang, S.; Vong, C.-L.; Wang, S.; Fang, R.; Li, L.; Wang, P.G.; Massion, P.; Ji, X. Identification of lipid biomarker from serum in patients with chronic obstructive pulmonary disease. *Respir. Res.* **2020**, *21*, 242. [[CrossRef](#)]
53. Long, J.; Yang, Z.; Wang, L.; Han, Y.; Peng, C.; Yan, C.; Yan, D. Metabolite biomarkers of type 2 diabetes mellitus and pre-diabetes: A systematic review and meta-analysis. *BMC Endocr. Disord.* **2020**, *20*, 174. [[CrossRef](#)] [[PubMed](#)]
54. Shah, V.; Shah, J. Recent trends in targeting miRNAs for cancer therapy. *J. Pharm. Pharmacol.* **2020**, *72*, 1732–1749. [[CrossRef](#)] [[PubMed](#)]

55. Uzuner, E.; Ulu, G.T.; Gürler, S.B.; Baran, Y. The Role of MiRNA in Cancer: Pathogenesis, Diagnosis, and Treatment. In *miRNomics: MicroRNA Biology and Computational Analysis*; Methods in Molecular Biology; Allmer, J., Yousef, M., Eds.; Springer: New York, NY, USA, 2022; pp. 375–422. ISBN 978-1-07-161170-8.
56. Tan, W.; Liu, B.; Qu, S.; Liang, G.; Luo, W.; Gong, C. MicroRNAs and cancer: Key paradigms in molecular therapy. *Oncol. Lett.* **2018**, *15*, 2735–2742. [[CrossRef](#)] [[PubMed](#)]
57. Peng, Y.; Croce, C.M. The role of MicroRNAs in human cancer. *Signal Transduct. Target. Ther.* **2016**, *1*, 15004. [[CrossRef](#)]
58. Lee, R.C.; Feinbaum, R.L.; Ambros, V. The *C. elegans* heterochronic gene *lin-4* encodes small RNAs with antisense complementarity to *lin-14*. *Cell* **1993**, *75*, 843–854. [[CrossRef](#)]
59. Wightman, B.; Ha, I.; Ruvkun, G. Posttranscriptional regulation of the heterochronic gene *lin-14* by *lin-4* mediates temporal pattern formation in *C. elegans*. *Cell* **1993**, *75*, 855–862. [[CrossRef](#)]
60. Kim, V.N.; Han, J.; Siomi, M.C. Biogenesis of small RNAs in animals. *Nat. Rev. Mol. Cell Biol.* **2009**, *10*, 126–139. [[CrossRef](#)]
61. Han, J.; Lee, Y.; Yeom, K.-H.; Kim, Y.-K.; Jin, H.; Kim, V.N. The Drosha-DGCR8 complex in primary microRNA processing. *Genes Dev.* **2004**, *18*, 3016–3027. [[CrossRef](#)]
62. Lee, Y.; Ahn, C.; Han, J.; Choi, H.; Kim, J.; Yim, J.; Lee, J.; Provost, P.; Rådmark, O.; Kim, S.; et al. The nuclear RNase III Drosha initiates microRNA processing. *Nature* **2003**, *425*, 415–419. [[CrossRef](#)]
63. Denli, A.M.; Tops, B.B.J.; Plasterk, R.H.A.; Ketting, R.F.; Hannon, G.J. Processing of primary microRNAs by the Microprocessor complex. *Nature* **2004**, *432*, 231–235. [[CrossRef](#)]
64. Yi, R.; Qin, Y.; Macara, I.G.; Cullen, B.R. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. *Genes Dev.* **2003**, *17*, 3011–3016. [[CrossRef](#)] [[PubMed](#)]
65. Sheng, P.; Fields, C.; Aadland, K.; Wei, T.; Kolaczowski, O.; Gu, T.; Kolaczowski, B.; Xie, M. Dicer cleaves 5'-extended microRNA precursors originating from RNA polymerase II transcription start sites. *Nucleic Acids Res.* **2018**, *46*, 5737–5752. [[CrossRef](#)] [[PubMed](#)]
66. Ketting, R.F.; Fischer, S.E.J.; Bernstein, E.; Sijen, T.; Hannon, G.J.; Plasterk, R.H.A. Dicer functions in RNA interference and in synthesis of small RNA involved in developmental timing in *C. elegans*. *Genes Dev.* **2001**, *15*, 2654–2659. [[CrossRef](#)] [[PubMed](#)]
67. Bhaskaran, M.; Mohan, M. MicroRNAs: History, biogenesis, and their evolving role in animal development and disease. *Vet. Pathol.* **2014**, *51*, 759–774. [[CrossRef](#)] [[PubMed](#)]
68. Salzman, D.W.; Shubert-Coleman, J.; Furneaux, H. P68 RNA helicase unwinds the human *let-7* microRNA precursor duplex and is required for *let-7*-directed silencing of gene expression. *J. Biol. Chem.* **2007**, *282*, 32773–32779. [[CrossRef](#)] [[PubMed](#)]
69. Albanese, M.; Chen, Y.-F.A.; Hüls, C.; Gärtner, K.; Tagawa, T.; Mejias-Perez, E.; Keppler, O.T.; Göbel, C.; Zeidler, R.; Shein, M.; et al. MicroRNAs are minor constituents of extracellular vesicles that are rarely delivered to target cells. *PLoS Genet.* **2021**, *17*, e1009951. [[CrossRef](#)] [[PubMed](#)]
70. Sohel, M.H. Extracellular/Circulating MicroRNAs: Release Mechanisms, Functions and Challenges. *Achiev. Life Sci.* **2016**, *10*, 175–186. [[CrossRef](#)]
71. Valadi, H.; Ekström, K.; Bossios, A.; Sjöstrand, M.; Lee, J.J.; Lötvall, J.O. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. *Nat. Cell Biol.* **2007**, *9*, 654–659. [[CrossRef](#)]
72. Pegtel, D.M.; Cosmopoulos, K.; Thorley-Lawson, D.A.; van Eijndhoven, M.A.J.; Hopmans, E.S.; Lindenberg, J.L.; de Gruijl, T.D.; Würdinger, T.; Middeldorp, J.M. Functional delivery of viral miRNAs via exosomes. *Proc. Natl. Acad. Sci. USA* **2010**, *107*, 6328–6333. [[CrossRef](#)]
73. Montecalvo, A.; Larregina, A.T.; Shufesky, W.J.; Beer Stolz, D.; Sullivan, M.L.G.; Karlsson, J.M.; Baty, C.J.; Gibson, G.A.; Erdos, G.; Wang, Z.; et al. Mechanism of transfer of functional microRNAs between mouse dendritic cells via exosomes. *Blood* **2012**, *119*, 756–766. [[CrossRef](#)]
74. Mittelbrunn, M.; Gutiérrez-Vázquez, C.; Villarroya-Beltri, C.; González, S.; Sánchez-Cabo, F.; González, M.Á.; Bernad, A.; Sánchez-Madrid, F. Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells. *Nat. Commun.* **2011**, *2*, 282. [[CrossRef](#)] [[PubMed](#)]
75. Arroyo, J.D.; Chevillet, J.R.; Kroh, E.M.; Ruf, I.K.; Pritchard, C.C.; Gibson, D.F.; Mitchell, P.S.; Bennett, C.F.; Pogosova-Agadjanyan, E.L.; Stirewalt, D.L.; et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. *Proc. Natl. Acad. Sci. USA* **2011**, *108*, 5003–5008. [[CrossRef](#)] [[PubMed](#)]
76. Chen, X.; Ba, Y.; Ma, L.; Cai, X.; Yin, Y.; Wang, K.; Guo, J.; Zhang, Y.; Chen, J.; Guo, X.; et al. Characterization of microRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseases. *Cell Res.* **2008**, *18*, 997–1006. [[CrossRef](#)] [[PubMed](#)]
77. Mompeón, A.; Ortega-Paz, L.; Vidal-Gómez, X.; Costa, T.J.; Pérez-Cremades, D.; Garcia-Blas, S.; Brugaletta, S.; Sanchis, J.; Sabate, M.; Novella, S.; et al. Disparate miRNA expression in serum and plasma of patients with acute myocardial infarction: A systematic and paired comparative analysis. *Sci. Rep.* **2020**, *10*, 5373. [[CrossRef](#)] [[PubMed](#)]
78. Aftab, M.; Poojary, S.S.; Seshan, V.; Kumar, S.; Agarwal, P.; Tandon, S.; Zutshi, V.; Das, B.C. Urine miRNA signature as a potential non-invasive diagnostic and prognostic biomarker in cervical cancer. *Sci. Rep.* **2021**, *11*, 10323. [[CrossRef](#)]
79. Carrillo-Lozano, E.; Sebastián-Valles, F.; Knott-Torcal, C. Circulating microRNAs in Breast Milk and Their Potential Impact on the Infant. *Nutrients* **2020**, *12*, 3066. [[CrossRef](#)]
80. Setti, G.; Pezzi, M.E.; Viani, M.V.; Pertinhez, T.A.; Cassi, D.; Magnoni, C.; Bellini, P.; Musolino, A.; Vescovi, P.; Meleti, M. Salivary MicroRNA for Diagnosis of Cancer and Systemic Diseases: A Systematic Review. *Int. J. Mol. Sci.* **2020**, *21*, 907. [[CrossRef](#)]

81. Kenny, A.; Jiménez-Mateos, E.M.; Zea-Sevilla, M.A.; Rábano, A.; Gili-Manzanaro, P.; Prehn, J.H.M.; Henshall, D.C.; Ávila, J.; Engel, T.; Hernández, F. Proteins and microRNAs are differentially expressed in tear fluid from patients with Alzheimer's disease. *Sci. Rep.* **2019**, *9*, 15437. [[CrossRef](#)]
82. Pan, Z.; Yang, G.; He, H.; Gao, P.; Jiang, T.; Chen, Y.; Zhao, G. Identification of Cerebrospinal Fluid MicroRNAs Associated With Leptomeningeal Metastasis From Lung Adenocarcinoma. *Front. Oncol.* **2020**, *10*, 387. [[CrossRef](#)] [[PubMed](#)]
83. Jansson, M.D.; Lund, A.H. MicroRNA and cancer. *Mol. Oncol.* **2012**, *6*, 590–610. [[CrossRef](#)]
84. Lytle, J.R.; Yario, T.A.; Steitz, J.A. Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5' UTR as in the 3' UTR. *Proc. Natl. Acad. Sci. USA* **2007**, *104*, 9667–9672. [[CrossRef](#)] [[PubMed](#)]
85. Ørom, U.A.; Nielsen, F.C.; Lund, A.H. MicroRNA-10a Binds the 5' UTR of Ribosomal Protein mRNAs and Enhances Their Translation. *Mol. Cell* **2008**, *30*, 460–471. [[CrossRef](#)] [[PubMed](#)]
86. Qin, W.; Shi, Y.; Zhao, B.; Yao, C.; Jin, L.; Ma, J.; Jin, Y. miR-24 Regulates Apoptosis by Targeting the Open Reading Frame (ORF) Region of FAF1 in Cancer Cells. *PLoS ONE* **2010**, *5*, e9429. [[CrossRef](#)] [[PubMed](#)]
87. Anglicheau, D.; Muthukumar, T.; Suthanthiran, M. MicroRNAs: Small RNAs with Big Effects. *Transplantation* **2010**, *90*, 105–112. [[CrossRef](#)]
88. Shyu, A.-B.; Wilkinson, M.F.; van Hoof, A. Messenger RNA regulation: To translate or to degrade. *EMBO J.* **2008**, *27*, 471–481. [[CrossRef](#)]
89. Bartel, D.P. MicroRNAs: Genomics, biogenesis, mechanism, and function. *Cell* **2004**, *116*, 281–297. [[CrossRef](#)]
90. Théry, C.; Witwer, K.W.; Aikawa, E.; Alcaraz, M.J.; Anderson, J.D.; Andriantsitohaina, R.; Antoniou, A.; Arab, T.; Archer, F.; Atkin-Smith, G.K.; et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): A position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. *J. Extracell. Ves.* **2018**, *7*, 1535750. [[CrossRef](#)]
91. Mayor, S.; Pagano, R.E. Pathways of clathrin-independent endocytosis. *Nat. Rev. Mol. Cell Biol.* **2007**, *8*, 603–612. [[CrossRef](#)]
92. Huotari, J.; Helenius, A. Endosome maturation. *EMBO J.* **2011**, *30*, 3481–3500. [[CrossRef](#)]
93. Keller, S.; Sanderson, M.P.; Stoeck, A.; Altevogt, P. Exosomes: From biogenesis and secretion to biological function. *Immunol. Lett.* **2006**, *107*, 102–108. [[CrossRef](#)]
94. Bebelman, M.P.; Smit, M.J.; Pegtel, D.M.; Baglio, S.R. Biogenesis and function of extracellular vesicles in cancer. *Pharmacol. Ther.* **2018**, *188*, 1–11. [[CrossRef](#)] [[PubMed](#)]
95. Cocucci, E.; Racchetti, G.; Meldolesi, J. Shedding microvesicles: Artefacts no more. *Trends Cell Biol.* **2009**, *19*, 43–51. [[CrossRef](#)] [[PubMed](#)]
96. Heijnen, H.F.; Schiel, A.E.; Fijnheer, R.; Geuze, H.J.; Sixma, J.J. Activated platelets release two types of membrane vesicles: Microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules. *Blood* **1999**, *94*, 3791–3799. [[CrossRef](#)] [[PubMed](#)]
97. Doyle, L.M.; Wang, M.Z. Overview of Extracellular Vesicles, Their Origin, Composition, Purpose, and Methods for Exosome Isolation and Analysis. *Cells* **2019**, *8*, 727. [[CrossRef](#)]
98. Kakarla, R.; Hur, J.; Kim, Y.J.; Kim, J.; Chwae, Y.-J. Apoptotic cell-derived exosomes: Messages from dying cells. *Exp. Mol. Med.* **2020**, *52*, 1–6. [[CrossRef](#)]
99. Barros, F.M.; Carneiro, F.; Machado, J.C.; Melo, S.A. Exosomes and Immune Response in Cancer: Friends or Foes? *Front. Immunol.* **2018**, *9*, 730. [[CrossRef](#)]
100. Ye, P.; Shi, Y.; An, N.; Zhou, Q.; Guo, J.; Long, X. miR-145 overexpression triggers alteration of the whole transcriptome and inhibits breast cancer development. *Biomed. Pharmacother.* **2018**, *100*, 72–82. [[CrossRef](#)]
101. Tang, R.; Li, L.; Zhu, D.; Hou, D.; Cao, T.; Gu, H.; Zhang, J.; Chen, J.; Zhang, C.-Y.; Zen, K. Mouse miRNA-709 directly regulates miRNA-15a/16-1 biogenesis at the posttranscriptional level in the nucleus: Evidence for a microRNA hierarchy system. *Cell Res.* **2012**, *22*, 504–515. [[CrossRef](#)]
102. Iorio, M.V.; Croce, C.M. MicroRNA dysregulation in cancer: Diagnostics, monitoring and therapeutics. A comprehensive review. *EMBO Mol. Med.* **2012**, *4*, 143–159. [[CrossRef](#)]
103. Calin, G.A.; Sevignani, C.; Dumitru, C.D.; Hyslop, T.; Noch, E.; Yendamuri, S.; Shimizu, M.; Rattan, S.; Bullrich, F.; Negrini, M.; et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. *Proc. Natl. Acad. Sci. USA* **2004**, *101*, 2999–3004. [[CrossRef](#)]
104. Calin, G.A.; Dumitru, C.D.; Shimizu, M.; Bichi, R.; Zupo, S.; Noch, E.; Aldler, H.; Rattan, S.; Keating, M.; Rai, K.; et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. *Proc. Natl. Acad. Sci. USA* **2002**, *99*, 15524–15529. [[CrossRef](#)] [[PubMed](#)]
105. Izumchenko, E.; Chang, X.; Michailidi, C.; Kagohara, L.; Ravi, R.; Paz, K.; Brait, M.; Hoque, M.O.; Ling, S.; Bedi, A.; et al. The TGFβ–miR200–MIG6 Pathway Orchestrates the EMT-Associated Kinase Switch That Induces Resistance to EGFR Inhibitors. *Cancer Res.* **2014**, *74*, 3995–4005. [[CrossRef](#)] [[PubMed](#)]
106. Di Leva, G.; Garofalo, M.; Croce, C.M. MicroRNAs in Cancer. *Annu. Rev. Pathol. Mech. Dis.* **2014**, *9*, 287–314. [[CrossRef](#)] [[PubMed](#)]
107. Croce, C.M. Causes and consequences of microRNA dysregulation in cancer. *Nat. Rev. Genet.* **2009**, *10*, 704–714. [[CrossRef](#)] [[PubMed](#)]
108. PIVA, R.; SPANDIDOS, D.A.; GAMBARI, R. From microRNA functions to microRNA therapeutics: Novel targets and novel drugs in breast cancer research and treatment. *Int. J. Oncol.* **2013**, *43*, 985–994. [[CrossRef](#)]

109. Wagner, S.; Willenbrock, S.; Nolte, I.; Murua Escobar, H. Comparison of non-coding RNAs in human and canine cancer. *Front. Genet.* **2013**, *4*, 46. [[CrossRef](#)]
110. Boggs, R.M.; Wright, Z.M.; Stickney, M.J.; Porter, W.W.; Murphy, K.E. MicroRNA expression in canine mammary cancer. *Mamm. Genome* **2008**, *19*, 561–569. [[CrossRef](#)]
111. Jeong, S.-J.; Lee, K.-H.; Nam, A.-R.; Cho, J.-Y. Genome-Wide Methylation Profiling in Canine Mammary Tumor Reveals miRNA Candidates Associated with Human Breast Cancer. *Cancers* **2019**, *11*, 1466. [[CrossRef](#)]
112. Hytönen, M.K.; Lohi, H. Canine models of human rare disorders. *Rare Dis.* **2016**, *4*, e1241362. [[CrossRef](#)]
113. Bulkowska, M.; Rybicka, A.; Senses, K.M.; Ulewicz, K.; Witt, K.; Szymanska, J.; Taciak, B.; Klopffleisch, R.; Hellmén, E.; Dolka, I.; et al. MicroRNA expression patterns in canine mammary cancer show significant differences between metastatic and non-metastatic tumours. *BMC Cancer* **2017**, *17*, 728. [[CrossRef](#)]
114. Von Deetzen, M.-C.; Schmeck, B.T.; Gruber, A.D.; Klopffleisch, R. Malignancy Associated MicroRNA Expression Changes in Canine Mammary Cancer of Different Malignancies. *ISRN Vet. Sci.* **2014**, *2014*, 148597. [[CrossRef](#)] [[PubMed](#)]
115. Łosiewicz, K.; Chmielewska-Krzysińska, M.; Socha, P.; Jakimiuk, A.; Wasowicz, K. MiRNA-21, miRNA-10b, and miRNA-34a Expression in Canine Mammary Gland Neoplasms. *J. Vet. Res.* **2014**, *58*, 447–451. [[CrossRef](#)]
116. Osaki, T.; Sunden, Y.; Sugiyama, A.; Azuma, K.; Murahata, Y.; Tsuka, T.; Ito, N.; Imagawa, T.; Okamoto, Y. Establishment of a canine mammary gland tumor cell line and characterization of its miRNA expression. *J. Vet. Sci.* **2016**, *17*, 385–390. [[CrossRef](#)] [[PubMed](#)]
117. Lutful Kabir, F.M.; DeInnocentes, P.; Bird, R.C. Altered microRNA Expression Profiles and Regulation of INK4A/CDKN2A Tumor Suppressor Genes in Canine Breast Cancer Models. *J. Cell. Biochem.* **2015**, *116*, 2956–2969. [[CrossRef](#)]
118. Zhang, T.; Feng, X.; Zhou, T.; Zhou, N.; Shi, X.; Zhu, X.; Qiu, J.; Deng, G.; Qiu, C. miR-497 induces apoptosis by the IRAK2/NF-κB axis in the canine mammary tumour. *Vet. Comp. Oncol.* **2021**, *19*, 69–78. [[CrossRef](#)]
119. Jain, M.; Ingole, S.D.; Deshmukh, R.S.; Bharucha, S.V.; Nagvekar, A.S.; Gaikwad, R.V.; Kharde, S.D. CEA, CA 15-3, and miRNA expression as potential biomarkers in canine mammary tumors. *Chromosome Res.* **2021**, *29*, 175–188. [[CrossRef](#)]
120. Ramadan, E.S.; Salem, N.Y.; Emam, I.A.; AbdelKader, N.A.; Farghali, H.A.; Khattab, M.S. MicroRNA-21 expression, serum tumor markers, and immunohistochemistry in canine mammary tumors. *Vet. Res. Commun.* **2021**. [[CrossRef](#)]
121. Fish, E.J.; Martinez-Romero, E.G.; DeInnocentes, P.; Koehler, J.W.; Prasad, N.; Smith, A.N.; Bird, R.C. Circulating microRNA as biomarkers of canine mammary carcinoma in dogs. *J. Vet. Intern. Med.* **2020**, *34*, 1282–1290. [[CrossRef](#)]
122. Feng, Y.-H.; Tsao, C.-J. Emerging role of microRNA-21 in cancer. *Biomed. Rep.* **2016**, *5*, 395–402. [[CrossRef](#)]
123. Krichevsky, A.M.; Gabriely, G. miR-21: A small multi-faceted RNA. *J. Cell. Mol. Med.* **2009**, *13*, 39–53. [[CrossRef](#)]
124. Jenike, A.E.; Halushka, M.K. miR-21: A non-specific biomarker of all maladies. *Biomark. Res.* **2021**, *9*, 18. [[CrossRef](#)] [[PubMed](#)]
125. Chan, J.A.; Krichevsky, A.M.; Kosik, K.S. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. *Cancer Res.* **2005**, *65*, 6029–6033. [[CrossRef](#)] [[PubMed](#)]
126. Medina, P.P.; Nolde, M.; Slack, F.J. OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. *Nature* **2010**, *467*, 86–90. [[CrossRef](#)] [[PubMed](#)]
127. Yan, L.-X.; Huang, X.-F.; Shao, Q.; Huang, M.-Y.; Deng, L.; Wu, Q.-L.; Zeng, Y.-X.; Shao, J.-Y. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. *RNA* **2008**, *14*, 2348–2360. [[CrossRef](#)]
128. Iorio, M.V.; Ferracin, M.; Liu, C.-G.; Veronese, A.; Spizzo, R.; Sabbioni, S.; Magri, E.; Pedriali, M.; Fabbri, M.; Campiglio, M.; et al. MicroRNA Gene Expression Deregulation in Human Breast Cancer. *Cancer Res.* **2005**, *65*, 7065–7070. [[CrossRef](#)]
129. Zhang, C.; Liu, K.; Li, T.; Fang, J.; Ding, Y.; Sun, L.; Tu, T.; Jiang, X.; Du, S.; Hu, J.; et al. miR-21: A gene of dual regulation in breast cancer. *Int. J. Oncol.* **2016**, *48*, 161–172. [[CrossRef](#)]
130. Wang, H.; Tan, Z.; Hu, H.; Liu, H.; Wu, T.; Zheng, C.; Wang, X.; Luo, Z.; Wang, J.; Liu, S.; et al. microRNA-21 promotes breast cancer proliferation and metastasis by targeting LZTFL1. *BMC Cancer* **2019**, *19*, 738. [[CrossRef](#)]
131. Khalighfard, S.; Alizadeh, A.M.; Irani, S.; Omranipour, R. Plasma miR-21, miR-155, miR-10b, and Let-7a as the potential biomarkers for the monitoring of breast cancer patients. *Sci. Rep.* **2018**, *8*, 17981. [[CrossRef](#)]
132. Asaga, S.; Kuo, C.; Nguyen, T.; Terpenning, M.; Giuliano, A.E.; Hoon, D.S. Direct Serum Assay for MicroRNA-21 Concentrations in Early and Advanced Breast Cancer. *Clin. Chem.* **2011**, *57*, 84–91. [[CrossRef](#)]
133. Yan, L.X.; Wu, Q.N.; Zhang, Y.; Li, Y.Y.; Liao, D.Z.; Hou, J.H.; Fu, J.; Zeng, M.S.; Yun, J.P.; Wu, Q.L.; et al. Knockdown of miR-21 in human breast cancer cell lines inhibits proliferation, in vitro migration and in vivo tumor growth. *Breast Cancer Res. BCR* **2011**, *13*, R2. [[CrossRef](#)]
134. Dan, T.; Shastri, A.A.; Palagani, A.; Buraschi, S.; Neill, T.; Savage, J.E.; Kapoor, A.; DeAngelis, T.; Addya, S.; Camphausen, K.; et al. miR-21 Plays a Dual Role in Tumor Formation and Cytotoxic Response in Breast Tumors. *Cancers* **2021**, *13*, 888. [[CrossRef](#)] [[PubMed](#)]
135. Javanmard, S.H.; Vaseghi, G.; Ghasemi, A.; Rafiee, L.; Ferns, G.A.; Esfahani, H.N.; Nedaeinia, R. Therapeutic inhibition of microRNA-21 (miR-21) using locked-nucleic acid (LNA)-anti-miR and its effects on the biological behaviors of melanoma cancer cells in preclinical studies. *Cancer Cell Int.* **2020**, *20*, 384. [[CrossRef](#)] [[PubMed](#)]
136. Bonci, D. MicroRNA-21 as therapeutic target in cancer and cardiovascular disease. *Recent Pat. Cardiovasc. Drug Discov.* **2010**, *5*, 156–161. [[CrossRef](#)] [[PubMed](#)]

137. Wu, Z.; Huang, X.; Huang, X.; Zou, Q.; Guo, Y. The inhibitory role of Mir-29 in growth of breast cancer cells. *J. Exp. Clin. Cancer Res.* **2013**, *32*, 98. [[CrossRef](#)] [[PubMed](#)]
138. Kwon, J.J.; Factora, T.D.; Dey, S.; Kota, J. A Systematic Review of miR-29 in Cancer. *Mol. Ther. Oncolytics* **2018**, *12*, 173–194. [[CrossRef](#)] [[PubMed](#)]
139. Zhao, H.; Wilkie, T.; Deol, Y.; Sneh, A.; Ganju, A.; Basree, M.; Nasser, M.W.; Ganju, R.K. miR-29b defines the pro-/anti-proliferative effects of S100A7 in breast cancer. *Mol. Cancer* **2015**, *14*, 11. [[CrossRef](#)]
140. Chou, J.; Lin, J.H.; Brenot, A.; Kim, J.; Provot, S.; Werb, Z. GATA3 suppresses metastasis and modulates the tumour microenvironment by regulating microRNA-29b expression. *Nat. Cell Biol.* **2013**, *15*, 201–213. [[CrossRef](#)]
141. Jiang, H.; Zhang, G.; Wu, J.-H.; Jiang, C.-P. Diverse roles of miR-29 in cancer (Review). *Oncol. Rep.* **2014**, *31*, 1509–1516. [[CrossRef](#)]
142. Yan, B.; Guo, Q.; Fu, F.; Wang, Z.; Yin, Z.; Wei, Y.; Yang, J. The role of miR-29b in cancer: Regulation, function, and signaling. *OncoTargets Ther.* **2015**, *8*, 539–548. [[CrossRef](#)]
143. Wang, H.; An, X.; Yu, H.; Zhang, S.; Tang, B.; Zhang, X.; Li, Z. MiR-29b/TET1/ZEB2 signaling axis regulates metastatic properties and epithelial-mesenchymal transition in breast cancer cells. *Oncotarget* **2017**, *8*, 102119–102133. [[CrossRef](#)]
144. Wang, C.; Bian, Z.; Wei, D.; Zhang, J. miR-29b regulates migration of human breast cancer cells. *Mol. Cell. Biochem.* **2011**, *352*, 197–207. [[CrossRef](#)] [[PubMed](#)]
145. Taha, M.; Mitwally, N.; Soliman, A.S.; Yousef, E. Potential Diagnostic and Prognostic Utility of miR-141, miR-181b1, and miR-23b in Breast Cancer. *Int. J. Mol. Sci.* **2020**, *21*, 8589. [[CrossRef](#)] [[PubMed](#)]
146. Choi, S.K.; Kim, H.S.; Jin, T.; Hwang, E.H.; Jung, M.; Moon, W.K. Overexpression of the miR-141/200c cluster promotes the migratory and invasive ability of triple-negative breast cancer cells through the activation of the FAK and PI3K/AKT signaling pathways by secreting VEGF-A. *BMC Cancer* **2016**, *16*, 570. [[CrossRef](#)]
147. Cava, C.; Novello, C.; Martelli, C.; Lo Dico, A.; Ottobri, L.; Piccotti, F.; Truffi, M.; Corsi, F.; Bertoli, G.; Castiglioni, I. Theranostic application of miR-429 in HER2+ breast cancer. *Theranostics* **2020**, *10*, 50–61. [[CrossRef](#)] [[PubMed](#)]
148. Song, C.; Liu, L.-Z.; Pei, X.-Q.; Liu, X.; Yang, L.; Ye, F.; Xie, X.; Chen, J.; Tang, H.; Xie, X. miR-200c inhibits breast cancer proliferation by targeting KRAS. *Oncotarget* **2015**, *6*, 34968–34978. [[CrossRef](#)] [[PubMed](#)]
149. Chen, J.; Tian, W.; He, H.; Chen, F.; Huang, J.; Wang, X.; Chen, Z. Downregulation of miR-200c-3p contributes to the resistance of breast cancer cells to paclitaxel by targeting SOX2. *Oncol. Rep.* **2018**, *40*, 3821–3829. [[CrossRef](#)]
150. Chen, H.; Li, Z.; Zhang, L.; Zhang, L.; Zhang, Y.; Wang, Y.; Xu, M.; Zhong, Q. MicroRNA-200c Inhibits the Metastasis of Triple-Negative Breast Cancer by Targeting ZEB2, an Epithelial-Mesenchymal Transition Regulator. *Ann. Clin. Lab. Sci.* **2020**, *50*, 519–527. [[PubMed](#)]
151. Lehmann, U.; Streichert, T.; Otto, B.; Albat, C.; Hasemeier, B.; Christgen, H.; Schipper, E.; Hille, U.; Kreipe, H.H.; Länger, F. Identification of differentially expressed microRNAs in human male breast cancer. *BMC Cancer* **2010**, *10*, 109. [[CrossRef](#)]
152. Shen, L.; Li, J.; Xu, L.; Ma, J.; Li, H.; Xiao, X.; Zhao, J.; Fang, L. miR-497 induces apoptosis of breast cancer cells by targeting Bcl-w. *Exp. Ther. Med.* **2012**, *3*, 475–480. [[CrossRef](#)]
153. Wei, C.; Luo, Q.; Sun, X.; Li, D.; Song, H.; Li, X.; Song, J.; Hua, K.; Fang, L. microRNA-497 induces cell apoptosis by negatively regulating Bcl-2 protein expression at the posttranscriptional level in human breast cancer. *Int. J. Clin. Exp. Pathol.* **2015**, *8*, 7729–7739.
154. Li, Y.; Hua, K.; Jin, J.; Fang, L. miR-497 inhibits proliferation and invasion in triple-negative breast cancer cells via YAP1. *Oncol. Lett.* **2021**, *22*, 580. [[CrossRef](#)] [[PubMed](#)]
155. Wu, Z.; Cai, X.; Huang, C.; Xu, J.; Liu, A. miR-497 suppresses angiogenesis in breast carcinoma by targeting HIF-1 α . *Oncol. Rep.* **2016**, *35*, 1696–1702. [[CrossRef](#)] [[PubMed](#)]
156. Luo, Q.; Li, X.; Gao, Y.; Long, Y.; Chen, L.; Huang, Y.; Fang, L. MiRNA-497 regulates cell growth and invasion by targeting cyclin E1 in breast cancer. *Cancer Cell Int.* **2013**, *13*, 95. [[CrossRef](#)] [[PubMed](#)]
157. Kulshreshtha, R.; Ferracin, M.; Wojcik, S.E.; Garzon, R.; Alder, H.; Agosto-Perez, F.J.; Davuluri, R.; Liu, C.-G.; Croce, C.M.; Negrini, M.; et al. A microRNA signature of hypoxia. *Mol. Cell. Biol.* **2007**, *27*, 1859–1867. [[CrossRef](#)]
158. Fasanaro, P.; D’Alessandra, Y.; Di Stefano, V.; Melchionna, R.; Romani, S.; Pompilio, G.; Capogrossi, M.C.; Martelli, F. MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3. *J. Biol. Chem.* **2008**, *283*, 15878–15883. [[CrossRef](#)]
159. WU, X. Expressions of miR-21 and miR-210 in Breast Cancer and Their Predictive Values for Prognosis. *Iran. J. Public Health* **2020**, *49*, 21–29. [[CrossRef](#)]
160. Pasculli, B.; Barbano, R.; Rendina, M.; Fontana, A.; Copetti, M.; Mazza, T.; Valori, V.M.; Morrìti, M.; Maiello, E.; Graziano, P.; et al. Hsa-miR-210-3p expression in breast cancer and its putative association with worse outcome in patients treated with Docetaxel. *Sci. Rep.* **2019**, *9*, 14913. [[CrossRef](#)]
161. Zhang, J.; Liu, D.; Feng, Z.; Mao, J.; Zhang, C.; Lu, Y.; Li, J.; Zhang, Q.; Li, Q.; Li, L. MicroRNA-138 modulates metastasis and EMT in breast cancer cells by targeting vimentin. *Biomed. Pharmacother.* **2016**, *77*, 135–141. [[CrossRef](#)]
162. Hong, Y.; Liang, H.; Uzair-ur-Rehman; Wang, Y.; Zhang, W.; Zhou, Y.; Chen, S.; Yu, M.; Cui, S.; Liu, M.; et al. miR-96 promotes cell proliferation, migration and invasion by targeting PTPN9 in breast cancer. *Sci. Rep.* **2016**, *6*, 37421. [[CrossRef](#)]
163. Bischoff, A.; Huck, B.; Keller, B.; Strotbek, M.; Schmid, S.; Boerries, M.; Busch, H.; Müller, D.; Olayioye, M.A. miR149 Functions as a Tumor Suppressor by Controlling Breast Epithelial Cell Migration and Invasion. *Cancer Res.* **2014**, *74*, 5256–5265. [[CrossRef](#)]

164. Sánchez-González, I.; Bobien, A.; Molnar, C.; Schmid, S.; Strotbek, M.; Boerries, M.; Busch, H.; Olayioye, M.A. miR-149 Suppresses Breast Cancer Metastasis by Blocking Paracrine Interactions with Macrophages. *Cancer Res.* **2020**, *80*, 1330–1341. [[CrossRef](#)] [[PubMed](#)]
165. Gantier, M.P.; McCoy, C.E.; Rusinova, I.; Saulep, D.; Wang, D.; Xu, D.; Irving, A.T.; Behlke, M.A.; Hertzog, P.J.; Mackay, F.; et al. Analysis of microRNA turnover in mammalian cells following Dicer1 ablation. *Nucleic Acids Res.* **2011**, *39*, 5692–5703. [[CrossRef](#)] [[PubMed](#)]
166. Minoura, K.; Sawada, Y.; Valer, M.; Wang, H. MicroRNA profiling is more stable than messenger RNA against RNA degradation. *Cancer Res.* **2008**, *68*, 5029.
167. Ye, J.; Xu, M.; Tian, X.; Cai, S.; Zeng, S. Research advances in the detection of miRNA. *J. Pharm. Anal.* **2019**, *9*, 217–226. [[CrossRef](#)] [[PubMed](#)]
168. Malczewska, A.; Kidd, M.; Matar, S.; Kos-Kudla, B.; Modlin, I.M. A Comprehensive Assessment of the Role of miRNAs as Biomarkers in Gastroenteropancreatic Neuroendocrine Tumors. *Neuroendocrinology* **2018**, *107*, 73–90. [[CrossRef](#)] [[PubMed](#)]
169. Sourvinou, I.S.; Markou, A.; Lianidou, E.S. Quantification of Circulating miRNAs in Plasma: Effect of Preanalytical and Analytical Parameters on Their Isolation and Stability. *J. Mol. Diagn.* **2013**, *15*, 827–834. [[CrossRef](#)]
170. Cui, M.; Wang, H.; Yao, X.; Zhang, D.; Xie, Y.; Cui, R.; Zhang, X. Circulating MicroRNAs in Cancer: Potential and Challenge. *Front. Genet.* **2019**, *10*, 626. [[CrossRef](#)]
171. Weber, J.A.; Baxter, D.H.; Zhang, S.; Huang, D.Y.; How Huang, K.; Jen Lee, M.; Galas, D.J.; Wang, K. The MicroRNA Spectrum in 12 Body Fluids. *Clin. Chem.* **2010**, *56*, 1733–1741. [[CrossRef](#)]
172. Hamam, R.; Hamam, D.; Alsaleh, K.A.; Kassem, M.; Zaher, W.; Alfayez, M.; Aldahmash, A.; Alajezi, N.M. Circulating microRNAs in breast cancer: Novel diagnostic and prognostic biomarkers. *Cell Death Dis.* **2017**, *8*, e3045. [[CrossRef](#)]
173. Kodahl, A.R.; Lyng, M.B.; Binder, H.; Cold, S.; Gravggaard, K.; Knoop, A.S.; Ditzel, H.J. Novel circulating microRNA signature as a potential non-invasive multi-marker test in ER-positive early-stage breast cancer: A case control study. *Mol. Oncol.* **2014**, *8*, 874–883. [[CrossRef](#)]
174. Liu, W.; Yeh, S.; Lu, C.; Yu, S.; Chen, H.; Lin, C.; Chen, D.; Chen, P. MicroRNA-18a Prevents Estrogen Receptor- α Expression, Promoting Proliferation of Hepatocellular Carcinoma Cells. *Gastroenterology* **2009**, *136*, 683–693. [[CrossRef](#)] [[PubMed](#)]
175. Luengo-Gil, G.; García-Martínez, E.; Chaves-Benito, A.; Conesa-Zamora, P.; Navarro-Manzano, E.; González-Billalabeitia, E.; García-Garre, E.; Martínez-Carrasco, A.; Vicente, V.; de la Peña, F.A. Clinical and biological impact of miR-18a expression in breast cancer after neoadjuvant chemotherapy. *Cell. Oncol.* **2019**, *42*, 627–644. [[CrossRef](#)] [[PubMed](#)]
176. Nair, M.G.; Prabhu, J.S.; Korlimarla, A.; Rajarajan, S.; Hari, P.S.; Kaul, R.; Alexander, A.; Raghavan, R.; Srinath, B.S.; Sridhar, T.S. miR-18a activates Wnt pathway in ER-positive breast cancer and is associated with poor prognosis. *Cancer Med.* **2020**, *9*, 5587–5597. [[CrossRef](#)] [[PubMed](#)]
177. Shidfar, A.; Costa, F.F.; Scholtens, D.; Bischof, J.M.; Sullivan, M.E.; Ivancic, D.Z.; Vanin, E.F.; Soares, M.B.; Wang, J.; Khan, S.A. Expression of miR-18a and miR-210 in Normal Breast Tissue as Candidate Biomarkers of Breast Cancer Risk. *Cancer Prev. Res.* **2017**, *10*, 89–97. [[CrossRef](#)]
178. Zhang, X.; Yu, H.; Lou, J.R.; Zheng, J.; Zhu, H.; Popescu, N.-I.; Lupu, F.; Lind, S.E.; Ding, W.-Q. MicroRNA-19 (miR-19) Regulates Tissue Factor Expression in Breast Cancer Cells. *J. Biol. Chem.* **2011**, *286*, 1429–1435. [[CrossRef](#)]
179. Zhao, L.; Zhao, Y.; He, Y.; Mao, Y. miR-19b promotes breast cancer metastasis through targeting MYLIP and its related cell adhesion molecules. *Oncotarget* **2017**, *8*, 64330–64343. [[CrossRef](#)]
180. Wang, H.; Peng, R.; Wang, J.; Qin, Z.; Xue, L. Circulating microRNAs as potential cancer biomarkers: The advantage and disadvantage. *Clin. Epigenet.* **2018**, *10*, 59. [[CrossRef](#)]
181. Nik Mohamed Kamal, N.N.S.B.; Shahidan, W.N.S. Non-Exosomal and Exosomal Circulatory MicroRNAs: Which Are More Valid as Biomarkers? *Front. Pharmacol.* **2020**, *10*, 1500. [[CrossRef](#)]
182. Dufourd, T.; Robil, N.; Mallet, D.; Carcenac, C.; Boulet, S.; Brishoual, S.; Rabois, E.; Houeto, J.-L.; de la Grange, P.; Carnicella, S. Plasma or serum? A qualitative study on rodents and humans using high-throughput microRNA sequencing for circulating biomarkers. *Biol. Methods Protoc.* **2019**, *4*, bpz006. [[CrossRef](#)]
183. Li, C.; Zhou, T.; Chen, J.; Li, R.; Chen, H.; Luo, S.; Chen, D.; Cai, C.; Li, W. The role of Exosomal miRNAs in cancer. *J. Transl. Med.* **2022**, *20*, 6. [[CrossRef](#)]
184. Jackson, C.E.; Scruggs, B.S.; Schaffer, J.E.; Hanson, P.I. Effects of Inhibiting VPS4 Support a General Role for ESCRTs in Extracellular Vesicle Biogenesis. *Biophys. J.* **2017**, *113*, 1342–1352. [[CrossRef](#)] [[PubMed](#)]
185. Cocucci, E.; Meldolesi, J. Ectosomes and exosomes: Shedding the confusion between extracellular vesicles. *Trends Cell Biol.* **2015**, *25*, 364–372. [[CrossRef](#)] [[PubMed](#)]
186. Stein, J.M.; Luzio, J.P. Ectocytosis caused by sublytic autologous complement attack on human neutrophils. The sorting of endogenous plasma-membrane proteins and lipids into shed vesicles. *Biochem. J.* **1991**, *274 Pt 2*, 381–386. [[CrossRef](#)] [[PubMed](#)]
187. Pan, B.-T.; Johnstone, R.M. Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: Selective externalization of the receptor. *Cell* **1983**, *33*, 967–978. [[CrossRef](#)]
188. Harding, C.; Heuser, J.; Stahl, P. Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes. *J. Cell Biol.* **1983**, *97*, 329–339. [[CrossRef](#)] [[PubMed](#)]

189. Yáñez-Mó, M.; Siljander, P.R.-M.; Andreu, Z.; Zavec, A.B.; Borràs, F.E.; Buzas, E.I.; Buzas, K.; Casal, E.; Cappello, F.; Carvalho, J.; et al. Biological properties of extracellular vesicles and their physiological functions. *J. Extracell. Ves.* **2015**, *4*, 27066. [[CrossRef](#)] [[PubMed](#)]
190. Johnstone, R.M.; Adam, M.; Hammond, J.R.; Orr, L.; Turbide, C. Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). *J. Biol. Chem.* **1987**, *262*, 9412–9420. [[CrossRef](#)]
191. Colombo, M.; Raposo, G.; Théry, C. Biogenesis, Secretion, and Intercellular Interactions of Exosomes and Other Extracellular Vesicles. *Annu. Rev. Cell Dev. Biol.* **2014**, *30*, 255–289. [[CrossRef](#)]
192. EL Andaloussi, S.; Mäger, I.; Breakefield, X.O.; Wood, M.J.A. Extracellular vesicles: Biology and emerging therapeutic opportunities. *Nat. Rev. Drug Discov.* **2013**, *12*, 347–357. [[CrossRef](#)]
193. Akers, J.C.; Gonda, D.; Kim, R.; Carter, B.S.; Chen, C.C. Biogenesis of extracellular vesicles (EV): Exosomes, microvesicles, retrovirus-like vesicles, and apoptotic bodies. *J. Neurooncol.* **2013**, *113*, 1–11. [[CrossRef](#)]
194. Baxter, A.A.; Phan, T.K.; Hanssen, E.; Liem, M.; Hulett, M.D.; Mathivanan, S.; Poon, I.K.H. Analysis of extracellular vesicles generated from monocytes under conditions of lytic cell death. *Sci. Rep.* **2019**, *9*, 7538. [[CrossRef](#)] [[PubMed](#)]
195. Konoshenko, M.Y.; Lekchnov, E.A.; Vlassov, A.V.; Laktionov, P.P. Isolation of Extracellular Vesicles: General Methodologies and Latest Trends. *BioMed Res. Int.* **2018**, *2018*, e8545347. [[CrossRef](#)] [[PubMed](#)]
196. Skotland, T.; Sagini, K.; Sandvig, K.; Llorente, A. An emerging focus on lipids in extracellular vesicles. *Adv. Drug Deliv. Rev.* **2020**, *159*, 308–321. [[CrossRef](#)] [[PubMed](#)]
197. Zhang, H.; Freitas, D.; Kim, H.S.; Fabijanic, K.; Li, Z.; Chen, H.; Mark, M.T.; Molina, H.; Martin, A.B.; Bojmar, L.; et al. Identification of distinct nanoparticles and subsets of extracellular vesicles by asymmetric flow field-flow fractionation. *Nat. Cell Biol.* **2018**, *20*, 332–343. [[CrossRef](#)]
198. Sahu, R.; Kaushik, S.; Clement, C.C.; Cannizzo, E.S.; Scharf, B.; Follenzi, A.; Potolicchio, I.; Nieves, E.; Cuervo, A.M.; Santambrogio, L. Microautophagy of Cytosolic Proteins by Late Endosomes. *Dev. Cell* **2011**, *20*, 131–139. [[CrossRef](#)] [[PubMed](#)]
199. Raposo, G.; Stoorvogel, W. Extracellular vesicles: Exosomes, microvesicles, and friends. *J. Cell Biol.* **2013**, *200*, 373–383. [[CrossRef](#)]
200. Möbius, W.; Ohno-Iwashita, Y.; van Donselaar, E.G.; Oorschot, V.M.J.; Shimada, Y.; Fujimoto, T.; Heijnen, H.F.G.; Geuze, H.J.; Slot, J.W. Immunoelectron Microscopic Localization of Cholesterol Using Biotinylated and Non-cytolytic Perfringolysin O. *J. Histochem. Cytochem.* **2002**, *50*, 43–55. [[CrossRef](#)]
201. Wollert, T.; Hurley, J.H. Molecular mechanism of multivesicular body biogenesis by ESCRT complexes. *Nature* **2010**, *464*, 864–869. [[CrossRef](#)]
202. Hessvik, N.P.; Llorente, A. Current knowledge on exosome biogenesis and release. *Cell. Mol. Life Sci.* **2018**, *75*, 193–208. [[CrossRef](#)]
203. Colombo, M.; Moita, C.; van Niel, G.; Kowal, J.; Vigneron, J.; Benaroch, P.; Manel, N.; Moita, L.F.; Théry, C.; Raposo, G. Analysis of ESCRT functions in exosome biogenesis, composition and secretion highlights the heterogeneity of extracellular vesicles. *J. Cell Sci.* **2013**, *126*, 5553–5565. [[CrossRef](#)]
204. Hurley, J.H.; Hanson, P.I. Membrane budding and scission by the ESCRT machinery: It's all in the neck. *Nat. Rev. Mol. Cell Biol.* **2010**, *11*, 556–566. [[CrossRef](#)] [[PubMed](#)]
205. Tian, X.; Shen, H.; Li, Z.; Wang, T.; Wang, S. Tumor-derived exosomes, myeloid-derived suppressor cells, and tumor microenvironment. *J. Hematol. Oncol.* **2019**, *12*, 84. [[CrossRef](#)] [[PubMed](#)]
206. Airola, M.V.; Hannun, Y.A. Sphingolipid Metabolism and Neutral Sphingomyelinases. In *Sphingolipids: Basic Science and Drug Development*; Handbook of Experimental Pharmacology; Gulbins, E., Petrache, I., Eds.; Springer: Vienna, Austria, 2013; pp. 57–76, ISBN 978-3-7091-1368-4.
207. Trajkovic, K.; Hsu, C.; Chiantia, S.; Rajendran, L.; Wenzel, D.; Wieland, F.; Schwille, P.; Brügger, B.; Simons, M. Ceramide Triggers Budding of Exosome Vesicles into Multivesicular Endosomes. *Science* **2008**, *319*, 1244–1247. [[CrossRef](#)] [[PubMed](#)]
208. King, H.W.; Michael, M.Z.; Gleadle, J.M. Hypoxic enhancement of exosome release by breast cancer cells. *BMC Cancer* **2012**, *12*, 421. [[CrossRef](#)]
209. Parolini, I.; Federici, C.; Raggi, C.; Lugini, L.; Palleschi, S.; De Milito, A.; Coscia, C.; Iessi, E.; Logozzi, M.; Molinari, A.; et al. Microenvironmental pH is a key factor for exosome traffic in tumor cells. *J. Biol. Chem.* **2009**, *284*, 34211–34222. [[CrossRef](#)]
210. Ciravolo, V.; Huber, V.; Ghedini, G.C.; Venturelli, E.; Bianchi, F.; Campiglio, M.; Morelli, D.; Villa, A.; Mina, P.D.; Menard, S.; et al. Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy. *J. Cell. Physiol.* **2012**, *227*, 658–667. [[CrossRef](#)]
211. Théry, C.; Zitvogel, L.; Amigorena, S. Exosomes: Composition, biogenesis and function. *Nat. Rev. Immunol.* **2002**, *2*, 569–579. [[CrossRef](#)]
212. Andreu, Z.; Yáñez-Mó, M. Tetraspanins in Extracellular Vesicle Formation and Function. *Front. Immunol.* **2014**, *5*, 442. [[CrossRef](#)]
213. Zhang, Y.; Liu, Y.; Liu, H.; Tang, W.H. Exosomes: Biogenesis, biologic function and clinical potential. *Cell Biosci.* **2019**, *9*, 19. [[CrossRef](#)]
214. Street, J.M.; Koritzinsky, E.H.; Glispie, D.M.; Star, R.A.; Yuen, P.S.T. Chapter Three-Urine Exosomes: An Emerging Trove of Biomarkers. In *Advances in Clinical Chemistry*; Makowski, G.S., Ed.; Elsevier: Amsterdam, The Netherlands, 2017; Volume 78, pp. 103–122.
215. Ding, X.-Q.; Wang, Z.-Y.; Xia, D.; Wang, R.-X.; Pan, X.-R.; Tong, J.-H. Proteomic Profiling of Serum Exosomes From Patients With Metastatic Gastric Cancer. *Front. Oncol.* **2020**, *10*, 1113. [[CrossRef](#)]

216. Qin, W.; Tsukasaki, Y.; Dasgupta, S.; Mukhopadhyay, N.; Ikebe, M.; Sauter, E.R. Exosomes in Human Breast Milk Promote EMT. *Clin. Cancer Res.* **2016**, *22*, 4517–4524. [[CrossRef](#)] [[PubMed](#)]
217. Villatoro, A.J.; del Carmen Martín-Astorga, M.; Alcoholado, C.; Becerra, J. Canine colostrum exosomes: Characterization and influence on the canine mesenchymal stem cell secretory profile and fibroblast anti-oxidative capacity. *BMC Vet. Res.* **2020**, *16*, 417. [[CrossRef](#)] [[PubMed](#)]
218. Keller, S.; Rupp, C.; Stoeck, A.; Runz, S.; Fogel, M.; Lugert, S.; Hager, H.-D.; Abdel-Bakky, M.S.; Gutwein, P.; Altevogt, P. CD24 is a marker of exosomes secreted into urine and amniotic fluid. *Kidney Int.* **2007**, *72*, 1095–1102. [[CrossRef](#)] [[PubMed](#)]
219. Inubushi, S.; Kawaguchi, H.; Mizumoto, S.; Kuniyama, T.; Baba, M.; Kitayama, Y.; Takeuchi, T.; Hoffman, R.M.; Sasaki, R. Oncogenic miRNAs Identified in Tear Exosomes From Metastatic Breast Cancer Patients. *Anticancer Res.* **2020**, *40*, 3091–3096. [[CrossRef](#)] [[PubMed](#)]
220. Zhao, Y.; Weber, S.R.; Lease, J.; Russo, M.; Siedlecki, C.A.; Xu, L.-C.; Chen, H.; Wang, W.; Ford, M.; Simó, R.; et al. Liquid Biopsy of Vitreous Reveals an Abundant Vesicle Population Consistent With the Size and Morphology of Exosomes. *Transl. Vis. Sci. Technol.* **2018**, *7*, 6. [[CrossRef](#)]
221. Dismuke, W.M.; Challa, P.; Navarro, I.; Stamer, W.D.; Liu, Y. Human aqueous humor exosomes. *Exp. Eye Res.* **2015**, *132*, 73–77. [[CrossRef](#)]
222. Gao, K.; Zhu, W.; Li, H.; Ma, D.; Liu, W.; Yu, W.; Wang, L.; Cao, Y.; Jiang, Y. Association between cytokines and exosomes in synovial fluid of individuals with knee osteoarthritis. *Mod. Rheumatol.* **2020**, *30*, 758–764. [[CrossRef](#)]
223. Machida, T.; Tomofuji, T.; Ekuni, D.; Maruyama, T.; Yoneda, T.; Kawabata, Y.; Mizuno, H.; Miyai, H.; Kunitomo, M.; Morita, M. MicroRNAs in Salivary Exosome as Potential Biomarkers of Aging. *Int. J. Mol. Sci.* **2015**, *16*, 21294–21309. [[CrossRef](#)]
224. Peng, P.; Yan, Y.; Keng, S. Exosomes in the ascites of ovarian cancer patients: Origin and effects on anti-tumor immunity. *Oncol. Rep.* **2011**, *25*, 749–762. [[CrossRef](#)]
225. Zhang, H.-G.; Grizzle, W.E. Exosomes: A novel pathway of local and distant intercellular communication that facilitates the growth and metastasis of neoplastic lesions. *Am. J. Pathol.* **2014**, *184*, 28–41. [[CrossRef](#)]
226. Zhou, X.; Xie, F.; Wang, L.; Zhang, L.; Zhang, S.; Fang, M.; Zhou, F. The function and clinical application of extracellular vesicles in innate immune regulation. *Cell. Mol. Immunol.* **2020**, *17*, 323–334. [[CrossRef](#)] [[PubMed](#)]
227. Shenoda, B.B.; Ajit, S.K. Modulation of Immune Responses by Exosomes Derived from Antigen-Presenting Cells. *Clin. Med. Insights Pathol.* **2016**, *9*, CPath-S39925. [[CrossRef](#)] [[PubMed](#)]
228. Bd, C.; Wy, W.; Mm, L.; Wc, C.; Bk, Y.; Yw, K.; Wc, T. Exosomes in Inflammation and Inflammatory Disease. *Proteomics* **2019**, *19*, 1800149. [[CrossRef](#)]
229. Zhang, H.; Lin, S.; McElroy, C.L.; Wang, B.; Jin, D.; Uteshev, V.V.; Jin, K. Circulating Pro-Inflammatory Exosomes Worsen Stroke Outcomes in Aging. *Circ. Res.* **2021**, *129*, e121–e140. [[CrossRef](#)] [[PubMed](#)]
230. Zou, Y.; Bhat, O.M.; Yuan, X.; Li, G.; Huang, D.; Guo, Y.; Zhou, D.; Li, P.-L. Release and Actions of Inflammatory Exosomes in Pulmonary Emphysema: Potential Therapeutic Target of Acupuncture. *J. Inflamm. Res.* **2021**, *14*, 3501–3521. [[CrossRef](#)] [[PubMed](#)]
231. Bahrami, A.; Binabaj, M.M.; Ferns, G.A. Exosomes: Emerging modulators of signal transduction in colorectal cancer from molecular understanding to clinical application. *Biomed. Pharmacother.* **2021**, *141*, 111882. [[CrossRef](#)]
232. Gangoda, L.; Boukouris, S.; Liem, M.; Kalra, H.; Mathivanan, S. Extracellular vesicles including exosomes are mediators of signal transduction: Are they protective or pathogenic? *Proteomics* **2015**, *15*, 260–271. [[CrossRef](#)]
233. Kawahara, H.; Hanayama, R. The Role of Exosomes/Extracellular Vesicles in Neural Signal Transduction. *Biol. Pharm. Bull.* **2018**, *41*, 1119–1125. [[CrossRef](#)]
234. Mao, Y.; Wang, Y.; Dong, L.; Zhang, Y.; Zhang, Y.; Wang, C.; Zhang, Q.; Yang, S.; Cao, L.; Zhang, X.; et al. Hypoxic exosomes facilitate angiogenesis and metastasis in esophageal squamous cell carcinoma through altering the phenotype and transcriptome of endothelial cells. *J. Exp. Clin. Cancer Res.* **2019**, *38*, 389. [[CrossRef](#)]
235. Olejarz, W.; Kubiak-Tomaszewska, G.; Chrzanowska, A.; Lorenc, T. Exosomes in Angiogenesis and Anti-angiogenic Therapy in Cancers. *Int. J. Mol. Sci.* **2020**, *21*, 5840. [[CrossRef](#)]
236. Chen, S.; Chen, X.; Luo, Q.; Liu, X.; Wang, X.; Cui, Z.; He, A.; He, S.; Jiang, Z.; Wu, N.; et al. Retinoblastoma cell-derived exosomes promote angiogenesis of human vesicle endothelial cells through microRNA-92a-3p. *Cell Death Dis.* **2021**, *12*, 695. [[CrossRef](#)] [[PubMed](#)]
237. Smith, V.L.; Cheng, Y.; Bryant, B.R.; Schorey, J.S. Exosomes function in antigen presentation during an in vivo Mycobacterium tuberculosis infection. *Sci. Rep.* **2017**, *7*, 43578. [[CrossRef](#)] [[PubMed](#)]
238. Arima, Y.; Liu, W.; Takahashi, Y.; Nishikawa, M.; Takakura, Y. Effects of Localization of Antigen Proteins in Antigen-Loaded Exosomes on Efficiency of Antigen Presentation. *Mol. Pharm.* **2019**, *16*, 2309–2314. [[CrossRef](#)] [[PubMed](#)]
239. Lindenbergh, M.F.S.; Wubbolts, R.; Borg, E.G.F.; Van't Veld, E.M.; Boes, M.; Stoorvogel, W. Dendritic cells release exosomes together with phagocytosed pathogen; potential implications for the role of exosomes in antigen presentation. *J. Extracell. Ves.* **2020**, *9*, 1798606. [[CrossRef](#)] [[PubMed](#)]
240. Bonafede, R.; Turano, E.; Scambi, I.; Busato, A.; Bontempi, P.; Virla, F.; Schiaffino, L.; Marzola, P.; Bonetti, B.; Mariotti, R. ASC-Exosomes Ameliorate the Disease Progression in SOD1(G93A) Murine Model Underlining Their Potential Therapeutic Use in Human ALS. *Int. J. Mol. Sci.* **2020**, *21*, 3651. [[CrossRef](#)] [[PubMed](#)]
241. Sun, T.; Ding, Z.-X.; Luo, X.; Liu, Q.-S.; Cheng, Y. Blood Exosomes Have Neuroprotective Effects in a Mouse Model of Parkinson's Disease. *Oxid. Med. Cell. Longev.* **2020**, *2020*, e3807476. [[CrossRef](#)] [[PubMed](#)]

242. Fayazi, N.; Sheykhasan, M.; Soleimani Asl, S.; Najafi, R. Stem Cell-Derived Exosomes: A New Strategy of Neurodegenerative Disease Treatment. *Mol. Neurobiol.* **2021**, *58*, 3494–3514. [[CrossRef](#)]
243. Jadli, A.S.; Parasor, A.; Gomes, K.P.; Shandilya, R.; Patel, V.B. Exosomes in Cardiovascular Diseases: Pathological Potential of Nano-Messenger. *Front. Cardiovasc. Med.* **2021**, *8*, 1483. [[CrossRef](#)]
244. Zeng, C.-Y.; Xu, J.; Liu, X.; Lu, Y.-Q. Cardioprotective Roles of Endothelial Progenitor Cell-Derived Exosomes. *Front. Cardiovasc. Med.* **2021**, *8*, 717536. [[CrossRef](#)]
245. Cao, C.; Wang, B.; Tang, J.; Zhao, J.; Guo, J.; Guo, Q.; Yue, X.; Zhang, Z.; Liu, G.; Zhang, H.; et al. Circulating exosomes repair endothelial cell damage by delivering miR-193a-5p. *J. Cell. Mol. Med.* **2021**, *25*, 2176–2189. [[CrossRef](#)]
246. Gang, D.; Yu, C.J.; Zhu, S.; Zhu, P.; Nasser, M.I. Application of mesenchymal stem cell-derived exosomes in kidney diseases. *Cell. Immunol.* **2021**, *364*, 104358. [[CrossRef](#)] [[PubMed](#)]
247. Lin, X.; Zhu, T.; Xu, F.; Zhong, J.-Y.; Li, F.; Shan, S.-K.; Wu, F.; Guo, B.; Zheng, M.-H.; Wang, Y.; et al. Plasma Exosomes Derived From Patients With End-Stage Renal Disease and Renal Transplant Recipients Have Different Effects on Vascular Calcification. *Front. Cell Dev. Biol.* **2021**, *8*, 1821. [[CrossRef](#)] [[PubMed](#)]
248. Ji, C.; Zhang, J.; Zhu, Y.; Shi, H.; Yin, S.; Sun, F.; Wang, Q.; Zhang, L.; Yan, Y.; Zhang, X.; et al. Exosomes derived from hucMSC attenuate renal fibrosis through CK1 δ / β -TRCP-mediated YAP degradation. *Cell Death Dis.* **2020**, *11*, 327. [[CrossRef](#)] [[PubMed](#)]
249. Saad, M.H.; Badierah, R.; Redwan, E.M.; El-Fakharany, E.M. A Comprehensive Insight into the Role of Exosomes in Viral Infection: Dual Faces Bearing Different Functions. *Pharmaceutics* **2021**, *13*, 1405. [[CrossRef](#)] [[PubMed](#)]
250. Xu, X.; Qian, J.; Ding, J.; Li, J.; Nan, F.; Wang, W.; Qin, Q.; Fei, Y.; Xue, C.; Wang, J.; et al. Detection of viral components in exosomes derived from NDV-infected DF-1 cells and their promoting ability in virus replication. *Microb. Pathog.* **2019**, *128*, 414–422. [[CrossRef](#)]
251. De Toledo Martins, S.; Alves, L.R. Extracellular Vesicles in Viral Infections: Two Sides of the Same Coin? *Front. Cell. Infect. Microbiol.* **2020**, *10*, 737. [[CrossRef](#)]
252. Sheller-Miller, S.; Trivedi, J.; Yellon, S.M.; Menon, R. Exosomes Cause Preterm Birth in Mice: Evidence for Paracrine Signaling in Pregnancy. *Sci. Rep.* **2019**, *9*, 608. [[CrossRef](#)]
253. Czernek, L.; D uchler, M. Exosomes as Messengers between Mother and Fetus in Pregnancy. *Int. J. Mol. Sci.* **2020**, *21*, 4264. [[CrossRef](#)]
254. Nair, S.; Salomon, C. Chapter 16—Potential role of exosomes in reproductive medicine and pregnancy. In *Exosomes*; Edelstein, L., Smythies, J., Quesenberry, P., Noble, D., Eds.; Academic Press: Cambridge, MA, USA, 2020; pp. 357–381, ISBN 978-0-12-816053-4.
255. Liu, Y.; Shi, K.; Chen, Y.; Wu, X.; Chen, Z.; Cao, K.; Tao, Y.; Chen, X.; Liao, J.; Zhou, J. Exosomes and Their Role in Cancer Progression. *Front. Oncol.* **2021**, *11*, 792. [[CrossRef](#)]
256. Lee, J.; Lee, S.-A.; Gu, N.-Y.; Jeong, S.Y.; Byeon, J.S.; Jeong, D.-U.; Ouh, I.-O.; Lee, Y.-H.; Hyun, B.-H. Canine Natural Killer Cell-Derived Exosomes Exhibit Antitumor Activity in a Mouse Model of Canine Mammary Tumor. *BioMed Res. Int.* **2021**, *2021*, e6690704. [[CrossRef](#)]
257. Brady, J.V.; Troyer, R.M.; Ramsey, S.A.; Leeper, H.; Yang, L.; Maier, C.S.; Goodall, C.P.; Ruby, C.E.; Albarqi, H.A.M.; Taratula, O.; et al. A Preliminary Proteomic Investigation of Circulating Exosomes and Discovery of Biomarkers Associated with the Progression of Osteosarcoma in a Clinical Model of Spontaneous Disease. *Transl. Oncol.* **2018**, *11*, 1137–1146. [[CrossRef](#)]
258. Li, M.; Liao, L.; Tian, W. Extracellular Vesicles Derived From Apoptotic Cells: An Essential Link Between Death and Regeneration. *Front. Cell Dev. Biol.* **2020**, *8*, 1063. [[CrossRef](#)] [[PubMed](#)]
259. Zhao, G.; Liu, F.; Liu, Z.; Zuo, K.; Wang, B.; Zhang, Y.; Han, X.; Lian, A.; Wang, Y.; Liu, M.; et al. MSC-derived exosomes attenuate cell death through suppressing AIF nucleus translocation and enhance cutaneous wound healing. *Stem Cell Res. Ther.* **2020**, *11*, 174. [[CrossRef](#)] [[PubMed](#)]
260. Zhou, M.; Weber, S.R.; Zhao, Y.; Chen, H.; Sundstrom, J.M. Chapter 2—Methods for exosome isolation and characterization. In *Exosomes*; Edelstein, L., Smythies, J., Quesenberry, P., Noble, D., Eds.; Academic Press: Cambridge, MA, USA, 2020; pp. 23–38, ISBN 978-0-12-816053-4.
261. Yang, D.; Zhang, W.; Zhang, H.; Zhang, F.; Chen, L.; Ma, L.; Larcher, L.M.; Chen, S.; Liu, N.; Zhao, Q.; et al. Progress, opportunity, and perspective on exosome isolation-efforts for efficient exosome-based theranostics. *Theranostics* **2020**, *10*, 3684–3707. [[CrossRef](#)] [[PubMed](#)]
262. Zhang, Y.; Bi, J.; Huang, J.; Tang, Y.; Du, S.; Li, P. Exosome: A Review of Its Classification, Isolation Techniques, Storage, Diagnostic and Targeted Therapy Applications. *Int. J. Nanomed.* **2020**, *15*, 6917–6934. [[CrossRef](#)]
263. Tang, Y.-T.; Huang, Y.-Y.; Zheng, L.; Qin, S.-H.; Xu, X.-P.; An, T.-X.; Xu, Y.; Wu, Y.-S.; Hu, X.-M.; Ping, B.-H.; et al. Comparison of isolation methods of exosomes and exosomal RNA from cell culture medium and serum. *Int. J. Mol. Med.* **2017**, *40*, 834–844. [[CrossRef](#)]
264. Patel, G.K.; Khan, M.A.; Zubair, H.; Srivastava, S.K.; Khushman, M.; Singh, S.; Singh, A.P. Comparative analysis of exosome isolation methods using culture supernatant for optimum yield, purity and downstream applications. *Sci. Rep.* **2019**, *9*, 5335. [[CrossRef](#)]
265. Skottvoll, F.S.; Berg, H.E.; Bj rseth, K.; Lund, K.; Roos, N.; Bekhradnia, S.; Thiede, B.; Sandberg, C.; Vik-Mo, E.O.; Roberg-Larsen, H.; et al. Ultracentrifugation versus kit exosome isolation: NanoLC–MS and other tools reveal similar performance biomarkers, but also contaminations. *Future Sci. OA* **2018**, *5*, FSO359. [[CrossRef](#)]

266. Jeyaram, A.; Jay, S.M. Preservation and Storage Stability of Extracellular Vesicles for Therapeutic Applications. *AAPS J.* **2017**, *20*, 1. [[CrossRef](#)]
267. Zhou, H.; Yuen, P.S.T.; Pisitkun, T.; Gonzales, P.A.; Yasuda, H.; Dear, J.W.; Gross, P.; Knepper, M.A.; Star, R.A. Collection, storage, preservation, and normalization of human urinary exosomes for biomarker discovery. *Kidney Int.* **2006**, *69*, 1471–1476. [[CrossRef](#)]
268. Ge, Q.; Zhou, Y.; Lu, J.; Bai, Y.; Xie, X.; Lu, Z. miRNA in Plasma Exosome is Stable under Different Storage Conditions. *Molecules* **2014**, *19*, 1568–1575. [[CrossRef](#)] [[PubMed](#)]
269. Muller, L.; Hong, C.-S.; Stolz, D.B.; Watkins, S.C.; Whiteside, T.L. Isolation of biologically-active exosomes from human plasma. *J. Immunol. Methods* **2014**, *411*, 55–65. [[CrossRef](#)] [[PubMed](#)]
270. Sarker, S.; Scholz-Romero, K.; Perez, A.; Illanes, S.E.; Mitchell, M.D.; Rice, G.E.; Salomon, C. Placenta-derived exosomes continuously increase in maternal circulation over the first trimester of pregnancy. *J. Transl. Med.* **2014**, *12*, 204. [[CrossRef](#)]
271. Cumba Garcia, L.M.; Peterson, T.E.; Cepeda, M.A.; Johnson, A.J.; Parney, I.F. Isolation and Analysis of Plasma-Derived Exosomes in Patients With Glioma. *Front. Oncol.* **2019**, *9*, 651. [[CrossRef](#)] [[PubMed](#)]
272. Enderle, D.; Spiel, A.; Coticchia, C.M.; Berghoff, E.; Mueller, R.; Schlumpberger, M.; Sprenger-Haussels, M.; Shaffer, J.M.; Lader, E.; Skog, J.; et al. Characterization of RNA from Exosomes and Other Extracellular Vesicles Isolated by a Novel Spin Column-Based Method. *PLoS ONE* **2015**, *10*, e0136133. [[CrossRef](#)] [[PubMed](#)]
273. Dutta, S.; Hornung, S.; Kruayatidee, A.; Maina, K.N.; del Rosario, I.; Paul, K.C.; Wong, D.Y.; Duarte Folle, A.; Markovic, D.; Palma, J.-A.; et al. α -Synuclein in blood exosomes immunoprecipitated using neuronal and oligodendroglial markers distinguishes Parkinson's disease from multiple system atrophy. *Acta Neuropathol.* **2021**, *142*, 495–511. [[CrossRef](#)]
274. Bazzan, E.; Tinè, M.; Casara, A.; Biondini, D.; Semenzato, U.; Cocconcelli, E.; Balestro, E.; Damin, M.; Radu, C.M.; Turato, G.; et al. Critical Review of the Evolution of Extracellular Vesicles' Knowledge: From 1946 to Today. *Int. J. Mol. Sci.* **2021**, *22*, 6417. [[CrossRef](#)]
275. Wang, L.; Zhang, L. Circulating Exosomal miRNA as Diagnostic Biomarkers of Neurodegenerative Diseases. *Front. Mol. Neurosci.* **2020**, *13*, 53. [[CrossRef](#)]
276. Jin, Y.; Ai, L.; Chai, X.; Tang, P.; Zhang, W.; Yang, L.; Hu, Y.; Xu, Y.; Li, S. Maternal Circulating Exosomal miRNAs as Non-invasive Biomarkers for the Prediction of Fetal Ventricular Septal Defect. *Front. Genet.* **2021**, *12*, 1659. [[CrossRef](#)]
277. Bhome, R.; Del Vecchio, F.; Lee, G.-H.; Bullock, M.D.; Primrose, J.N.; Sayan, A.E.; Mirnezami, A.H. Exosomal microRNAs (exomiRs): Small molecules with a big role in cancer. *Cancer Lett.* **2018**, *420*, 228–235. [[CrossRef](#)]
278. Thind, A.; Wilson, C. Exosomal miRNAs as cancer biomarkers and therapeutic targets. *J. Extracell. Ves.* **2016**, *5*, 31292. [[CrossRef](#)] [[PubMed](#)]
279. Koga, Y.; Yasunaga, M.; Moriya, Y.; Akasu, T.; Fujita, S.; Yamamoto, S.; Matsumura, Y. Exosome can prevent RNase from degrading microRNA in feces. *J. Gastrointest. Oncol.* **2011**, *2*, 215–222. [[CrossRef](#)] [[PubMed](#)]
280. Cheng, L.; Sun, X.; Scicluna, B.J.; Coleman, B.M.; Hill, A.F. Characterization and deep sequencing analysis of exosomal and non-exosomal miRNA in human urine. *Kidney Int.* **2014**, *86*, 433–444. [[CrossRef](#)] [[PubMed](#)]
281. Pritchard, C.C.; Cheng, H.H.; Tewari, M. MicroRNA profiling: Approaches and considerations. *Nat. Rev. Genet.* **2012**, *13*, 358–369. [[CrossRef](#)] [[PubMed](#)]
282. Xiao, C.-T.; Lai, W.-J.; Zhu, W.-A.; Wang, H. MicroRNA Derived from Circulating Exosomes as Noninvasive Biomarkers for Diagnosing Renal Cell Carcinoma. *OncoTargets Ther.* **2020**, *13*, 10765–10774. [[CrossRef](#)]
283. Tang, B.; Wu, Y.; Fang, H.; Wu, Y.; Shi, K. Small RNA Sequencing Reveals Exosomal miRNAs Involved in the Treatment of Asthma by Scorpio and Centipede. *BioMed Res. Int.* **2020**, *2020*, e1061407. [[CrossRef](#)]
284. Zhang, Y.; Han, T.; Feng, D.; Li, J.; Wu, M.; Peng, X.; Wang, B.; Zhan, X.; Fu, P. Screening of non-invasive miRNA biomarker candidates for metastasis of gastric cancer by small RNA sequencing of plasma exosomes. *Carcinogenesis* **2020**, *41*, 582–590. [[CrossRef](#)]
285. Abd Elmageed, Z.Y.; Yang, Y.; Thomas, R.; Ranjan, M.; Mondal, D.; Moroz, K.; Fang, Z.; Rezk, B.M.; Moparty, K.; Sikka, S.C.; et al. Neoplastic Reprogramming of Patient-Derived Adipose Stem Cells by Prostate Cancer Cell-Associated Exosomes. *Stem Cells* **2014**, *32*, 983–997. [[CrossRef](#)]
286. Whiteside, T.L. Tumor-derived exosomes and their role in cancer progression. *Adv. Clin. Chem.* **2016**, *74*, 103–141. [[CrossRef](#)]
287. Kharmate, G.; Hosseini-Beheshti, E.; Caradec, J.; Chin, M.Y.; Guns, E.S.T. Epidermal Growth Factor Receptor in Prostate Cancer Derived Exosomes. *PLoS ONE* **2016**, *11*, e0154967. [[CrossRef](#)]
288. Riches, A.; Campbell, E.; Borger, E.; Powis, S. Regulation of exosome release from mammary epithelial and breast cancer cells—A new regulatory pathway. *Eur. J. Cancer* **2014**, *50*, 1025–1034. [[CrossRef](#)] [[PubMed](#)]
289. Logozzi, M.; Milito, A.D.; Lugini, L.; Borghi, M.; Calabrò, L.; Spada, M.; Perdicchio, M.; Marino, M.L.; Federici, C.; Iessi, E.; et al. High Levels of Exosomes Expressing CD63 and Caveolin-1 in Plasma of Melanoma Patients. *PLoS ONE* **2009**, *4*, e5219. [[CrossRef](#)] [[PubMed](#)]
290. Melo, S.A.; Luecke, L.B.; Kahlert, C.; Fernandez, A.F.; Gammon, S.T.; Kaye, J.; LeBleu, V.S.; Mittendorf, E.A.; Weitz, J.; Rahbari, N.; et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. *Nature* **2015**, *523*, 177–182. [[CrossRef](#)] [[PubMed](#)]
291. Taylor, D.D.; Gercel-Taylor, C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. *Gynecol. Oncol.* **2008**, *110*, 13–21. [[CrossRef](#)]
292. Zhang, X.; Shi, H.; Yuan, X.; Jiang, P.; Qian, H.; Xu, W. Tumor-derived exosomes induce N2 polarization of neutrophils to promote gastric cancer cell migration. *Mol. Cancer* **2018**, *17*, 146. [[CrossRef](#)]

293. Yang, S.-S.; Ma, S.; Dou, H.; Liu, F.; Zhang, S.-Y.; Jiang, C.; Xiao, M.; Huang, Y.-X. Breast cancer-derived exosomes regulate cell invasion and metastasis in breast cancer via miR-146a to activate cancer associated fibroblasts in tumor microenvironment. *Exp. Cell Res.* **2020**, *391*, 111983. [[CrossRef](#)]
294. Ma, Z.; Wei, K.; Yang, F.; Guo, Z.; Pan, C.; He, Y.; Wang, J.; Li, Z.; Chen, L.; Chen, Y.; et al. Tumor-derived exosomal miR-3157-3p promotes angiogenesis, vascular permeability and metastasis by targeting TIMP/KLF2 in non-small cell lung cancer. *Cell Death Dis.* **2021**, *12*, 840. [[CrossRef](#)]
295. Yang, Z.; Zhao, N.; Cui, J.; Wu, H.; Xiong, J.; Peng, T. Exosomes derived from cancer stem cells of gemcitabine-resistant pancreatic cancer cells enhance drug resistance by delivering miR-210. *Cell. Oncol.* **2020**, *43*, 123–136. [[CrossRef](#)]
296. Wu, H.-J.; Hao, M.; Yeo, S.K.; Guan, J.-L. FAK signaling in cancer-associated fibroblasts promotes breast cancer cell migration and metastasis by exosomal miRNAs-mediated intercellular communication. *Oncogene* **2020**, *39*, 2539–2549. [[CrossRef](#)]
297. Fang, T.; Lv, H.; Lv, G.; Li, T.; Wang, C.; Han, Q.; Yu, L.; Su, B.; Guo, L.; Huang, S.; et al. Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer. *Nat. Commun.* **2018**, *9*, 191. [[CrossRef](#)]
298. Ding, G.; Zhou, L.; Qian, Y.; Fu, M.; Chen, J.; Chen, J.; Xiang, J.; Wu, Z.; Jiang, G.; Cao, L. Pancreatic cancer-derived exosomes transfer miRNAs to dendritic cells and inhibit RFXAP expression via miR-212-3p. *Oncotarget* **2015**, *6*, 29877–29888. [[CrossRef](#)] [[PubMed](#)]
299. Fang, Y.; Zhou, W.; Rong, Y.; Kuang, T.; Xu, X.; Wu, W.; Wang, D.; Lou, W. Exosomal miRNA-106b from cancer-associated fibroblast promotes gemcitabine resistance in pancreatic cancer. *Exp. Cell Res.* **2019**, *383*, 111543. [[CrossRef](#)] [[PubMed](#)]
300. Tang, Y.; Zhao, Y.; Song, X.; Song, X.; Niu, L.; Xie, L. Tumor-derived exosomal miRNA-320d as a biomarker for metastatic colorectal cancer. *J. Clin. Lab. Anal.* **2019**, *33*, e23004. [[CrossRef](#)] [[PubMed](#)]
301. Cho, H.J.; Eun, J.W.; Baek, G.O.; Seo, C.W.; Ahn, H.R.; Kim, S.S.; Cho, S.W.; Cheong, J.Y. Serum Exosomal MicroRNA, miR-10b-5p, as a Potential Diagnostic Biomarker for Early-Stage Hepatocellular Carcinoma. *J. Clin. Med.* **2020**, *9*, 281. [[CrossRef](#)]
302. Sun, S.; Chen, H.; Xu, C.; Zhang, Y.; Zhang, Q.; Chen, L.; Ding, Q.; Deng, Z. Exosomal miR-106b serves as a novel marker for lung cancer and promotes cancer metastasis via targeting PTEN. *Life Sci.* **2020**, *244*, 117297. [[CrossRef](#)]
303. Maeda, K.; Sasaki, H.; Ueda, S.; Miyamoto, S.; Terada, S.; Konishi, H.; Kogata, Y.; Ashihara, K.; Fujiwara, S.; Tanaka, Y.; et al. Serum exosomal microRNA-34a as a potential biomarker in epithelial ovarian cancer. *J. Ovarian Res.* **2020**, *13*, 47. [[CrossRef](#)]
304. Ichii, O.; Ohta, H.; Horino, T.; Nakamura, T.; Hosotani, M.; Mizoguchi, T.; Morishita, K.; Nakamura, K.; Hoshino, Y.; Takagi, S.; et al. Urinary exosome-derived microRNAs reflecting the changes of renal function and histopathology in dogs. *Sci. Rep.* **2017**, *7*, 40340. [[CrossRef](#)]
305. Yang, V.K.; Loughran, K.A.; Meola, D.M.; Juhr, C.M.; Thane, K.E.; Davis, A.M.; Hoffman, A.M. Circulating exosome microRNA associated with heart failure secondary to myxomatous mitral valve disease in a naturally occurring canine model. *J. Extracell. Ves.* **2017**, *6*, 1350088. [[CrossRef](#)]
306. El-Tookhy, O.S.; Shamaa, A.A.; Shehab, G.G.; Abdallah, A.N.; Azzam, O.M. Histological Evaluation of Experimentally Induced Critical Size Defect Skin Wounds Using Exosomal Solution of Mesenchymal Stem Cells Derived Microvesicles. *Int. J. Stem Cells* **2017**, *10*, 144–153. [[CrossRef](#)]
307. Troyer, R.M.; Ruby, C.E.; Goodall, C.P.; Yang, L.; Maier, C.S.; Albarqi, H.A.; Brady, J.V.; Bathke, K.; Taratula, O.; Mourich, D.; et al. Exosomes from Osteosarcoma and normal osteoblast differ in proteomic cargo and immunomodulatory effects on T cells. *Exp. Cell Res.* **2017**, *358*, 369–376. [[CrossRef](#)]
308. Howard, J.; Wyse, C.; Argyle, D.; Quinn, C.; Kelly, P.; McCann, A. Exosomes as Biomarkers of Human and Feline Mammary Tumours; A Comparative Medicine Approach to Unravelling the Aggressiveness of TNBC. *Biochim. Biophys. Acta Rev. Cancer* **2020**, *1874*, 188431. [[CrossRef](#)] [[PubMed](#)]
309. Fish, E.J.; Irizarry, K.J.; DeInnocentes, P.; Ellis, C.J.; Prasad, N.; Moss, A.G.; Curt Bird, R. Malignant canine mammary epithelial cells shed exosomes containing differentially expressed microRNA that regulate oncogenic networks. *BMC Cancer* **2018**, *18*, 832. [[CrossRef](#)] [[PubMed](#)]
310. Asada, H.; Tomiyasu, H.; Uchikai, T.; Ishihara, G.; Goto-Koshino, Y.; Ohno, K.; Tsujimoto, H. Comprehensive analysis of miRNA and protein profiles within exosomes derived from canine lymphoid tumour cell lines. *PLoS ONE* **2019**, *14*, e0208567. [[CrossRef](#)] [[PubMed](#)]
311. Agarwal, P.; Crepps, M.P.; Stahr, N.A.; Kretschmar, W.P.; Harris, H.C.; Prasad, N.; Levy, S.E.; Smith, B.F. Identification of canine circulating miRNAs as tumor biospecific markers using Next-Generation Sequencing and Q-RT-PCR. *Biochem. Biophys. Rep.* **2021**, *28*, 101106. [[CrossRef](#)]
312. Garnica, T.K.; Lesbon, J.C.C.; Ávila, A.C.F.C.M.; Rochetti, A.L.; Matiz, O.R.S.; Ribeiro, R.C.S.; Zoppa, A.; Nishiya, A.T.; Costa, M.T.; de Nardi, A.B.; et al. Liquid biopsy based on small extracellular vesicles predicts chemotherapy response of canine multicentric lymphomas. *Sci. Rep.* **2020**, *10*, 20371. [[CrossRef](#)]
313. Ramos-Zayas, Y.; Franco-Molina, M.A.; Hernández-Granados, A.J.; Zárate-Triviño, D.G.; Coronado-Cerda, E.E.; Mendoza-Gamboa, E.; Zapata-Benavides, P.; Ramírez-Romero, R.; Santana-Krymskaya, S.E.; Tamez-Guerra, R.; et al. Immunotherapy for the treatment of canine transmissible venereal tumor based in dendritic cells pulsed with tumoral exosomes. *Immunopharmacol. Immunotoxicol.* **2019**, *41*, 48–54. [[CrossRef](#)]
314. Husna, A.A.; Rahman, M.M.; Lai, Y.-C.; Chen, H.-W.; Hasan, M.N.; Nakagawa, T.; Miura, N. Identification of melanoma-specific exosomal miRNAs as the potential biomarker for canine oral melanoma. *Pigment Cell Melanoma Res.* **2021**, *34*, 1062–1073. [[CrossRef](#)]

315. Heishima, K.; Ichikawa, Y.; Yoshida, K.; Iwasaki, R.; Sakai, H.; Nakagawa, T.; Tanaka, Y.; Hoshino, Y.; Okamura, Y.; Murakami, M.; et al. Circulating microRNA-214 and -126 as potential biomarkers for canine neoplastic disease. *Sci. Rep.* **2017**, *7*, 2301. [[CrossRef](#)]
316. Sharma, T.; Hamilton, R.; Mandal, C.C. miR-214: A potential biomarker and therapeutic for different cancers. *Future Oncol. Lond. Engl.* **2015**, *11*, 349–363. [[CrossRef](#)]
317. Meister, J.; Schmidt, M.H.H. miR-126 and miR-126*: New players in cancer. *ScientificWorldJournal* **2010**, *10*, 2090–2100. [[CrossRef](#)]
318. Eichelser, C.; Stückrath, I.; Müller, V.; Milde-Langosch, K.; Wikman, H.; Pantel, K.; Schwarzenbach, H. Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients. *Oncotarget* **2014**, *5*, 9650–9663. [[CrossRef](#)] [[PubMed](#)]
319. Hannafon, B.N.; Trigos, Y.D.; Calloway, C.L.; Zhao, Y.D.; Lum, D.H.; Welm, A.L.; Zhao, Z.J.; Blick, K.E.; Dooley, W.C.; Ding, W.Q. Plasma exosome microRNAs are indicative of breast cancer. *Breast Cancer Res.* **2016**, *18*, 90. [[CrossRef](#)] [[PubMed](#)]
320. Singh, R.; Pochampally, R.; Watabe, K.; Lu, Z.; Mo, Y.-Y. Exosome-mediated transfer of miR-10b promotes cell invasion in breast cancer. *Mol. Cancer* **2014**, *13*, 256. [[CrossRef](#)] [[PubMed](#)]
321. O'Brien, K.; Lowry, M.C.; Corcoran, C.; Martinez, V.G.; Daly, M.; Rani, S.; Gallagher, W.M.; Radomski, M.W.; MacLeod, R.A.F.; O'Driscoll, L. miR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivity. *Oncotarget* **2015**, *6*, 32774–32789. [[CrossRef](#)] [[PubMed](#)]
322. Li, X.J.; Ren, Z.J.; Tang, J.H.; Yu, Q. Exosomal MicroRNA MiR-1246 Promotes Cell Proliferation, Invasion and Drug Resistance by Targeting CCNG2 in Breast Cancer. *Cell. Physiol. Biochem.* **2017**, *44*, 1741–1748. [[CrossRef](#)]
323. Sueta, A.; Yamamoto, Y.; Tomiguchi, M.; Takeshita, T.; Yamamoto-Ibusuki, M.; Iwase, H. Differential expression of exosomal miRNAs between breast cancer patients with and without recurrence. *Oncotarget* **2017**, *8*, 69934–69944. [[CrossRef](#)]